This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
T H E S Y N T H E S I S A N D C H A R A C T E R I Z A T I O N O F R U T H E N I U M D I S U L F O X I D E
C O M P L E X E S A N D T H E I R P R E L I M I N A R Y IN VITRO E X A M I N A T I O N A S
P O T E N T I A L C H E M O T H E R A P E U T I C A G E N T S
B y
L Y N S E Y A N N E H U X H A M
B . S c , University of British Columbia, 1998
A THESIS S U B M I T T E D I N P A R T I A L F U L F I L L M E N T O F
T H E R E Q U I R E M E N T S F O R T H E D E G R E E O F
M A S T E R O F S C I E N C E
In
T H E F A C U L T Y O F G R A D U A T E S T U D I E S
(Department of Chemistry)
We accept this thesis as conforming
to the required standard
T H E U N I V E R S I T Y O F B R I T I S H C O L U M B I A
M T T 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
xiii
O D optical density
O R T E P Oakridge Thermal Ell ipsoid Program
PBS phosphate buffered saline solution
P E plating efficiency
pta l,3,5-triaza-7-phosphatricycol[3.3.1.1]decane
r.t. room temperature
RB-flask round bottom flask
T M S tetramethylenesulfide
T M S O tetramethylenesulfoxide
A M molar conductivity
xiv
Acknowledgements
I would like to thank firstly my supervisor Dr. Brian James for his support and
guidance throughout this thesis work.
Many thanks also to Dr . Kirsten Skov, Jenny, and Janet from the B C Cancer Research
Centre for their endless help throughout the biological testing and specifically the C H O
toxicity assay. I am very grateful to the Biological Services Department and especially Dr.
Elena Polishchuk and Mona for their support and help in setting up the C H O toxicity assay.
A s well , I would like to thank Jason Sartor, also from the B C C R C , for his efforts in my
training during the M T T toxicity assay.
Many thanks to the departmental services at U B C namely M r . Peter Borda, the N M R
staff, and Dr. Brian Patrick.
Thanks also to past and present members of the James group for all their ideas,
suggestions, and encouragement.
Special thanks to my family and friends for all their love and support.
xv
Chapter 1
Chapter 1
Introduction:
Ruthenium Sulfoxide Complexes and their Anti-cancer Properties
1.1 Introduction
Cancer is a progressive disease characterized by abnormal, uncontrolled, and invasive
cell growth. Many cell types can be transformed into tumor cells by disruption or
disregulation of normal biochemical and cellular processes.1 In the industrialized Western
world the most common malignancies, which account for approximately 50% of all cancers,
are lung, breast, and colorectal cancer.' If these cancers are detected at an early stage, the
chosen treatments are surgery and/or radiation therapy. However, a more advanced,
metastatic form of the disease requires chemotherapy (direction of toxic compounds towards
malignant cells). Chemotherapy treatment is non-specific, targeting actively dividing cells, and generally only results in prolonged survival for the above mentioned cancers.'
Common chemotherapy agents are organic or natural products such as alkylating
2
agents, antibiotics, and alkaloids but, since the discovery of cisplatin (Section 1.2), metal
compounds have been used in chemotherapy treatments. Metals as biological agents can
participate in biological redox reactions, undergo ligand substitution with biological
molecules, or have potential as radioactive isotopes for tumor imaging or therapy.' The
development of Ru-based anti-cancer agents and their observed an ti-metastatic activity,
provide encouragement for the treatment of resistant tumors as well as prevention and 3,4
reduction of tumor metastases.
1 References on page 15
Chapter 1
1.2 Platinum Chemotherapeutic Agents
Since the serendipitous discovery of cell division inhibition by cisplatin [cis-
5
diamminedichloroplatinum(II)] in 1965, the complex has become one of the most active and
widely used anti-cancer drugs today.6 It is highly effective in the treatment of testicular and 7
ovarian cancers, and is also active against head and neck, lung, cervical, and bladder cancers
while breast cancer is recognized as a potential target of cisplatin.6 Cisplatin is administered
intravenously and has associated toxicity problems including nephrotoxicity, neurotoxcitiy, 7
nausea, and vomiting at the clinical dosage given. As well, several tumor types exhibit
recurrences, after treatment of the initial tumor, due to primary or secondary (acquired) 6
resistance to cisplatin. These problems have led to further investigation of Pt derivatives or
second generation Pt drugs for chemotherapy use. New Pt drug developments have
considered several characteristics including charge, lipophilicity, stability in the gastric
environment, oral bioavailability, and a cis arrangement (to permit intrastrand crosslinking of g
DNA) for the design and composition of new drugs. Carboplatin (diammine[l,l-
cyclobutanedicarboxylato]-0,0'-platinum(U)), a second generation drug, has achieved a 7
lower toxicity and is routinely clinically used. However, it is only effective in the same
range (tumor lines) as cisplatin and does not exhibit activity towards cisplatin resistant 7
tumors. Therefore further work has explored the expansion of the Pt(U) drug line, and of
Pt(IV) complexes as potential orally active drugs. Of note, selected trans-Pt complexes as
well as di- and tri-nuclear Pt complexes have shown anti-tumor activity, with a different
mechanism of action from that of cisplatin, and in particular one tri-nuclear complex has 7,9,10
shown reactivity in both cisplatin sensitive and resistant cell lines.
2 References on page 15
Chapter 1
The mechanism of action of cisplatin, after drug administration, involves diffusion of
the complex into cells where loss of chloride occurs in the intracellular environment of low
chloride concentration; the complex then becomes biologically active and can bind to D N A 6
The binding of D N A produces interstrand crosslinks (1-5% of lesions) and intrastrand
adducts (majority of lesions), the majority of intrastrand adducts being created by the binding
of cisplatin to two neighboring deoxyguanosines at the N7 positions (Figure 1.1); these
adducts produce local unwinding of the D N A and inhibit replication and transcription.6 It is
unclear, however, how this invokes cell death as all cells have mechanisms to repair damaged
DNA. Yet it is known that the damage caused by the binding of cisplatin also triggers a
cellular response involving activation of some genes, inactivation of other genes, and shifts
6 in cellular metabolism and cell cycle progression, triggering apoptosis.
N H 2
Figure 1.1 Structure of deoxyguanosine showing the N7 coordination site.
3 References on page 15
Chapter 1
1.3 Ruthenium Chemotherapeutic Agents
Once a cancer has metastasized (spread) to other regions of the body, the method of
treatment must be able to access the entire body, and therefore chemotherapy becomes the
treatment of choice. However, commonly used chemotherapy drugs, such as cisplatin, which
directly interfere with DNA affecting the cell division process are not specific to tumor cells.
The exploration of Ru complexes for use as chemotherapeutic agents was initiated in
attempts to find less toxic and more specific drugs. Six-coordinate, octahedral Ru agents
provide additional coordination sites compared with the square-planar Pt(LT) complexes, and
such sites may provide new DNA-binding modes and, depending on the ligands, chirality at
the metal centre leading to chiral interactions with the DNA helix.11 As well, Ru(II) and (HI)
complexes containing N-ligands are generally substitution inert suggesting they will bind
12
DNA and prevent replication. Ru complexes may utilize different methods of action from
those of Pt complexes, and therefore may provide a greater specificity for tumor cells, be
active towards different tumor lines than cisplatin, or active toward cisplatin-resistant tumors.
Ru agents have shown selectivity for solid tumor metastases and have a lack of 3
significant host toxicity at biologically active doses. The sequence of events thought to 13
occur when these complexes are injected into a living body are as follows (Steps 1-3): 14
1. The Ru moiety binds to transferrin and then is selectively distributed to
transferrin-rich receptor tissue.
2. Ru(JJJ) complexes undergo slow exchange reactions until reduction gives the
more labile Ru(IJ). 3. Ru exhibits a high DNA-binding affinity.
4 References on page 15
Chapter 1
This proposed behaviour suggests Ru agents may target tumor cells because
malignant cells upregulate the expression of transferrin receptors on the cell membrane due
12
to an increased iron requirement. Therefore Ru binding to transferrin provides a method of
specificity for ruthenium agents, not available for most of the commonly used anti-cancer 13
agents. The low capacity for exchange of Ru(HI) suggests Ru(nJ) complexes could be used 15
as "prodrugs" of the more active Ru(U) forms. Of note, tumor cells grow more rapidly then
normal cells, and as such require increased amounts of glucose and oxygen. 1 5 In fact, the
growth is so rapid that the neovascularization process cannot keep pace with the tumor cell
growth, and as a result regions of hypoxia form even only at micrometer distances from
blood capillaries.' 5 The Ru(m) "prodrugs" wi l l be relatively inert and non-active in the oxic
biological environment, but in the hypoxic environment of tumor cells reduction to Ru(II)
produces a labile complex that wi l l be active toward D N A . It follows that the high D N A -
binding affinity of R u suggests that the drug, once in the intracellular space, wi l l be able to
bind D N A .
Ruthenium(in) ammine complexes such as cz£-[RuCl2(NH3)4]Cl and JmH[trans-
Ru(Im)2Cl4] have shown cytotoxic effects in cell cultures related to D N A - b i n d i n g . 1 6 The
17
mode of DNA-binding is analogous to that of cisplatin (Section 1.2). These multichloro
complexes, as well a s / a c - f R u C ^ N H ^ ] , exhibit the best activity for ruthenium complexes , . 16
toward primary tumors.
5 References on page 15
Chapter 1
1.3.1 Ruthenium DimethylsulJvxide Complexes
Ru(IJ) and (HI) D M S O complexes exhibit anti-cancer activity at high doses, but are
1 8
relatively non-toxic at high concentrations with L D 5 0 values up to 1 g/Kg. Some of the
initial biological studies involved cis- and r r an5 - R u C l 2 ( D M S O ) 4 and suggested that these
complexes have anti-cancer properties and specifically anti-metastatic properties. Cis-
RuCl2(DMSO)4 is moderately active at very high doses against primary tumors of M C a 1 9
mammary carcinoma and B16 melanoma with survival times moderately increased, while
f ra /w-RuCl 2 (DMSO) 4 is active against both primary tumor and metastases formation of B16 1 6
melanoma. Both isomers show no statistically significant effect on primary tumor growth 20
of Lewis lung carcinoma, but do significantly lower lung metastases. Both complexes
reduced the number and weight of spontaneous lung metastases by 50 %, with trans-21
R u C l 2 ( D M S O ) 4 being slightly more active at a lower dose. In mice bearing Lewis lung
carcinoma, cisplatin is effective at 0.52 mg/(kg-day) compared with zrans-RuCl2(DMSO) 4, 21
which is effective at 37 mg/(kg-day) and cw-RuCl2(DMSO) 4 at 700 mg/(kg-day). In molar
terms cw-RuCl2(DMSO) 4 is active at 1238 u M and cisplatin at 1.7 u M showing that a much
higher dose is needed to produce an equi-toxic effect using the ruthenium complexes; 20,22
however, this is achieved with reduced host toxicity.
The solution activities of c w - R u C l 2 ( D M S O ) 3 ( D M S O ) and r ran^-RuCl 2 (DMSO) 4 are
different, thus leading to their different anti-cancer activity. C / s - R u C l 2 ( D M S O ) 4 , once 23
dissolved in H 2 0 , immediately loses the O-bound D M S O which is replaced by H 2 0 . This
is followed by slow dissociation of chloride over approximately 10 h to give a 1:1 electrolyte
with no further loss of chloride over time (Figure 1.2 (A)); this behaviour is seen at
6 References on page 15
Chapter 1
biological temperatures (37 °C) but a conductivity corresponding to a 1:1 electrolyte is
21
achieved after only 3 h. Alessio et al. have also shown that chloride dissociation occurs at
a chloride concentration of 3 m M (intracellular concentration) but is completely inhibited at 21
150 m M (extracellular concentration). This implies that c i s - R u C ^ C D M S O ^ loses D M S O in the extracellular environment with no chloride dissociation, and the resulting neutral
species is able to diffuse across the cell membrane where, once inside the cell, it wi l l lose
chloride and become active. In contrast, rratts-RuCl2(DMSO)4 on dissolution in H2O
immediately releases two S-bound D M S O molecules, and becomes a c/s-diaquo, cis-
bis(DMSO), rrans-chloro species (Figure 1.2 (BJ); the release of two S-bound D M S O
molecules is thought to occur due to the unfavourable frans-effects between trans S-bound
21 molecules. The neutral trans isomer then slowly loses chloride, over approximately a 24 h
21 period, and after 6 days loses the second chloride. Under biological conditions, the trans
isomer loses chloride over more than 6 h and this solution activity is also inhibited at chloride
21 concentrations of 150 m M .
7 References on page 15
Chapter 1
Figure 1.2 The aqueous solution chemistry of c/s-RuCl2(DMSO)4 (A) and trans-R u C l 2 ( D M S O ) 4 (B), where S = S-bound D M S O , and O = O-bound D M S O (adapted from ref. 21).
Work in this laboratory has investigated the synthesis of
24,25
RuCl2(sulfoxide)2(nitroimidazole)2 complexes as biological radiosensitizers, while
26
complexes such as Na[rra/M-RuCl4(DMSO)(L)] (L = NH3 or imidazole (lm)) were
developed as potential anti-cancer agents. Two complexes, shown in Figure 1.3, Na[trans-
RuCl 4 (DMSO)(Im)] ( N A M I ) and ImH[rran5-RuCl 4(DMSO)(Im)] ( N A M I - A ) represent an
important development in anti-cancer treatment because of their an ti-metastatic activity 16
which could be vital in eliminating micrometastases following surgery.
8 References on page 15
Chapter 1
Figure 1.3 The structures of N A M I (C = Na) and N A M I - A (C = ImH), where S = S-bound D M S O (adapted from ref. 3).
N A M I and N A M I - A are active against M C a mammary carcinoma and Lewis lung
16
carcinoma, while only N A M I is active against B16 melanoma. N A M I does not work by
binding to D N A and preventing replication, but instead may act to increase resistance to the 3
formation of metastases. The complex appears to alter the ratio between m R N A s of M M P 2
(a metalloproteinase capable of degrading the extracellular matrix) and TEVIP-2 (the specific 27,28
tissue inhibitor of this enzyme), thereby causing a pronounced increase in extracellular
matrix components in and around the tumor, and this hinders the formation of metastases, 16
and blood flow to the tumor. N A M I - A has pharmacological properties and activity similar 16
to those of N A M I ; however, it is more stable and the synthesis is more reproducible.
1.3.2 DNA-binding of cis-RuCl2(DMSO)4 and trans-RuCl2(DMSO)4
29
7Vans-RuCl2(DMSO)4 reacts in vitro and in vivo with D N A , and shows a mechanism 30
of action similar to that of cisplatin even though it has a different geometry. Alessio et al.
have shown using N M R spectroscopy and C D that reaction of f n m s - R u C ^ D M S O ^ with
5 ' G M P forms [RuCl (H 2 0) (DMSO) 2 (5 ' -GMP)]" ; two diastereomers with opposite chirality at 31
the Ru are formed upon chelation via the N7 and the a-phosphate group. The N7 site of the 9 References on page 15
Chapter 1
guanine bases is the preferred site of attack on D N A , and studies by Esposito et al. using
N M R spectroscopy and molecular modeling have shown reaction between trans-
RuCl2(DMSO) 4 and the dinucleotide d(GpG) results in the formation of a 1,2 intrastrand
crosslink. 3 2
Reactions of c i 5 - R u C l 2 ( D M S O ) 4 with adenine and cytosine produce
Ru 2(ade)3(DMSO) 3Cl4 and R u 2 ( c y t ) 4 ( D M S O ) 2 C l 4 ( C H 3 O H ) 4 , respectively, as shown by
33
elemental and IR analysis. Tian et al. have shown, using and 3 1 P N M R spectroscopy
evidence, that under physiological conditions d s - R u C l 2 ( D M S O ) 4 reacts with 5 ' - G M P ,
coordinating via the N7 and phosphate group, to form predominantly two isomers with
opposite chirality at the R u (Figure 1.4); however, the major product from reaction of cis-34
R u C l 2 ( D M S O ) 4 with 5 ' - A M P has only coordinated phosphate.
O ii,,, iN
. R u , N „nS
' C l C l . R u
Figure 1.4 Structures of the diastereomers formed by the reaction of a's-RuCl2(DMSO) 4
and 5 ' G M P ; N represents the N7 of the guanine base and O represents an O-atom of the phosphate group (adapted from ref. 34).
A study by Davey et al, using electrospray ionization mass spectrometry and 'Ft
N M R spectroscopy, details the reaction products of cz's-RuCl2(DMSO) 4 and trans-
RuCl2(DMSO) 4 with 2'-deoxyguanosine (2'-dG). Both complexes react, via different
pathways, to give identical end-products, 2 diastereomers with the 2 ' -dG coordinated via the
10 References on page 15
Chapter 1
N7, and a bis adduct with two N7-coordinated 2 ' -dG moieties (Figure 1.5); also, both cis-
R u C l 2 ( D M S O ) 4 and trans-RuC\2(DMSO)4 react with 2'-deoxyadenosine (coordinated via N l )
to some degree, while the trans isomer reacts to a small extent with 2'-deoxycytidine and not
35 at all with thymidine.
Q H 2 O H 2
S 2'-dG . 2 '-dG ^ R u " ^ R U :
$r ^ O H 2 H o O ^ I
'S
(1)
2'-dG 2'-dG
O H 2
S1 ,„«i'2'-dG
ST | ^ 2 ' - d G C l
(2)
Figure 1.5 The structure of (1) the two diastereomers formed upon reaction of cis- and ?rans-RuCl 2 (DMSO) 4 with 2 ' -dG, and (2) a third end-product formed upon further reaction with 2 ' -dG (adapted from ref. 35).
1.3.3 Ruthenium Disulfoxide Complexes
Work in the James group extended the range of Ru(sulfoxide) complexes to include
36,37
disulfoxide complexes, both to examine their in vitro activity and to reduce the number of
possible isomers formed during the preparation of RuCl2(sulfoxide)2(nitroimidazole)2 24,25
complexes. Yapp isolated and examined the in vitro toxicity, cell accumulation, and
DNA-binding ability of disulfoxide complexes of the formula cz's-RuCl2(L)2 [L = 1,2-
bis(ethylsulfinyl)ethane (BESE) , and l,3-bis(methylsulfinyl)propane (BMSP)] , and trans-
11 References on page 15
Chapter 1
R u C l 2 ( L ) 2 [ L = l,2-bis(methylsulfinyl)ethane (BMSE) , and l,2-bis(propylsulfinyl)ethane
36,37
(BPSE)]. Further studies by Cheu led to isolation of c w - R u C l 2 ( L ) 2 [L = 1,2-
The disulfoxides used in this thesis work are of the formula R S ( 0 ) ( C H 2 ) n S ( 0 ) R (n =
2, and R = Et (BESE) , or Ph (BPhSE); or n = 3, and R = Et (BESP), or Pr (BPSP)), of which
B E S E (l,2-bis(ethylsulfinyl)ethane) was synthesized and isolated as a mixture of
diastereomers (rac-R,R/S,S pairs, and meso-R,S/S,R forms) and recrystallized from E t O H as
15 the meso isomer. O f note, separation of enantiomeric forms of B P h S E (1,2-
16,17
bis(phenylsulfinyl)ethane) has been achieved by column chromatography on lactose,
while enantiomers of B M S E (l,2-bis(methylsulfinyl)ethane) and B E S E have been 18
synthesized using diacetone-D-glucose and purified by column chromatography on silica.
X-ray crystal structures of B M S E , B P S E (l,2-bis(propylsulfinyl)ethane), and B P h S E have
suggested that generally the higher melting isomer, obtained from the synthetic procedure 19
involving oxidation of the dithioether with D M S O , is the meso form.
41 References on page 75
Chapter 3
Madan et al. have synthesized various metal disulfoxide complexes of the formulas
[ M ( B M S E ) 3 ] ( C 1 0 4 ) 2 ( M = M n 2 + , F e 2 + , C o 2 + , N i 2 + , C u 2 + , Z n 2 + , C d 2 + ) , and M C 1 2 ( B M S E ) ( M =
2+ 2+ 2 0
Pt , Pd ). A s well , complexes with other sulfoxides of the formula [ M ( L ) n ] ( 0 0 4 ) 2 [n = 3
and M = M n 2 + , C o 2 + , N i 2 + , Z n 2 + ;n = 2 and M = C u 2 + ; L = B E S E , B M S P (1,3
bis(methylsulfinyl)propane), and B M S B (1,4 bis(methylsulfinyl)butane)] were later 21
synthesized. IR spectroscopy studies of all these complexes suggest that the sulfoxides are
O-bound (shift to a lower v s o ) , except for the P t 2 + and P d 2 + complexes which are S-bound
(shift to a higher v s o ) . Musgrave and Kent have synthesized complexes of the formula
[M(L) 3 ] (C10 4 ) 2 ( M = C o 2 + , N i 2 + , C u 2 + ; L = meso- and rac-BPhSM {bis(phenylsulfinyl)methane}, and meso- and rac-BPhSE) all with O-bound sulfoxides and
22
the platinum complexes P t ( L ) C l 2 (L = meso- and rac-BPhSE) with S-bound sulfoxides.
Khiar et al. have synthesized Fe(HI) complexes with the enantiomerically pure
ligands (S,S)-bis(p-tolylsulfinyl)methane and (S,S)-2,2-bis(p-tolylsulfinyl)propane that are O-23
bonded. Tokunoh et al. have synthesized (S,S)-l,2-bis(p-tolylsulfinyl)benzene (BTSB) and
the complexes [Rh(BTSB)(COD)](C10 4 ) , f rans-RuCl 2 (BTSB) 2 and P d C l 2 ( B T S B ) containing 24
S-bound sulfoxides. Synthesis and characterization of Rh complexes with chiral sulfoxides
such as p-tolyl methyl sulfoxide, and Ru complexes with chiral disulfoxides such as dios,
[(2/?3/?)-2,3-0-isopropylidene-2,3-dihydroxy-l,4-bis(methylsulfinyl)butane] were studied as 25,26
catalysts for asymmetric hydrogenation of prochiral olefins. The Khiar group has
synthesized and purified, by column chromatography, enantiomerically pure B E S E and
B M S E and R u complexes of the formula rran^-RuCl 2 (L) 2 (L = 7?,7?/S,5-BESE and R,R/S,S-
4 2 References on page 75
Chapter 3
18 B M S E ) . The B M S E complexes have undergone preliminary biological testing and IC50
18 data for both complexes are presented in Chapter 4 (Section 4.7.1).
27
Complexes such as Na[rrans-RuCl 4 (R 2 SO)(L)] and mer,cw-RuCl 3 (R 2 SO)(L) (L =
NH3 or imidazole; R 2 S O = D M S O , and T M S O ) have been synthesized as potential anti
cancer agents (Chapter 1), and some of the initial biological work in this laboratory looked at
synthesizing RuCl 2 (R 2 SO) 2 (ni t roimidazole) 2 as potential radiosensitizers, but the structures
of the complexes were not definitively resolved because of the number of possible isomers 28,29
formed. The use of sulfoxides was extended to include disulfoxides, both to reduce the
number of isomers formed in preparation of the nitroimidazole complexes and to further the
range of possible R u sulfoxide anti-tumor complexes. Further work on disulfoxides by Yapp
et al. led to the isolation of cw-RuCl 2 (L ) 2 (L = B M S P , and B E S E ) and frans-RuCl 2 (L) 2 (L =
B M S E , and B P S E ) , all of which contain S-bound sulfoxide as established by X-ray 30,31
diffraction. A s well , Cheu has isolated cw-RuCl 2 (L ) 2 (L = B B S E , BPeSE , B C y S E , and
B E S P ) and r r a n 5 - R u C l 2 ( L ) 2 H 2 0 (L = B E S E and BPSE) , all of which show S-bound
sulfoxide by X-ray structure characterization, except for the B P e S E complex which was 32
indicated to be S-bound by IR data. Cheu has also isolated (by using one equivalent of
disulfoxide per Ru) and characterized chloride-bridged, dinuclear complexes of the formula
[ R u C l ( L ) ( H 2 0 ) ] 2 t > C l ) 2 (L = B E S E , B P S E , and B B S E ) of which only the B E S E complex
was structurally characterized, but all complexes indicate S-bound sulfoxide as shown by LR 32
data. A Ru(II)/(III) dinuclear complex [RuCl(BPSP)] 2(jU-Cl) 3 was also synthesized by
using two equivalents of disulfoxide, and this was structurally characterized to reveal S-32
bound sulfoxide. Work in this thesis has led to isolation and characterization of the mixed
43 References on page 75
Chapter 3
sulfoxide complex c « - R u C l 2 ( D M S O ) 2 ( B E S E ) with one O-bound D M S O , one S-bound
D M S O , and S-bound disulfoxide.
3.3.1 Cis-RuCl2(DMSO)2(BESE)
C w - R u C l 2 ( D M S O ) 2 ( B E S E ) , in a 69 % yield, was synthesized from
[RuCl (BESE)(H 2 0) ] 2 ( / i -C l ) 2 and D M S O , and was isolated as a pale yellow precipitate that
did not need further purification. Crystals suitable for X-ray diffraction were grown by slow
evaporation of a solution of the complex in a 1:1 mixture of E t O H / C H 2 C l 2 . The O R T E P
diagram (Figure 3.2) shows the structure with cis chlorides, a chelating S-bound meso-BESE
(the chirality at S ( l ) is R and at S(2) is 5), one S-bound D M S O , and one O-bound D M S O .
Tables 3.1 and 3.2 show various bond lengths and bond angles, respectively, of the title
complex, d s - R u C l 2 ( D M S O ) 4 , and m - R u C l 2 ( B E S E ) 2 . The S-O bond lengths for all S-bound
sulfoxides fall in the region of 1.470-1.485 A, as expected (Section 3.2.1), showing the S-O
bond has some double bond character (cf. 1.531(5) A of free D M S O ) . The S-O bond lengths
for O-bound D M S O are 1.529(3) and 1.557(4) A for c « - R u C l 2 ( D M S O ) 2 ( B E S E ) and cis-
RuCl 2 (DMSO)4, respectively; these longer bond lengths are expected for O-bound sulfoxide
due to electron density donation from the O-atom to the metal (Section 3.2.2). The R u - C l
bond lengths are relatively long (Section 3.2) for all three complexes and range from 2.42(1)-
2.44(8) A, and suggest that D M S O and B E S E are poor 7i-acceptors.
44 References on page 75
Figure 3.2 A molecular structure representation (ORTEP) of c« -RuCl 2 (DMSO) 2 (BESE) with 50% probability thermal ellipsoids shown; H-atoms are omitted for clarity (a stereoview and crystal data are given in Appendix 1 ) .
45 References on page 75
Chapter 3
The mainly S-bound sulfoxide implies a "soft" character of Ru(II). For cw-
R u C l 2 ( D M S O ) 2 ( B E S E ) , the Ru-S bond lengths trans to chloride are slightly longer (2.283
and 2.250 A) than that trans to oxygen (2.214 A). The shorter Ru-S bond length suggests
more 7i-back donation from Ru to the S-donor when the S-bound sulfoxide is trans to the O-
atom. Both cz ' s -RuCl 2 (DMSO) 2 (BESE) and cz 's-RuCl 2 (DMSO) 4 have one O-bound D M S O ,
perhaps due to steric hindrance, which is trans to an S-atom to avoid 71-back-bonding
competition between trans sulfur ligands, as outlined in Section 3.2.1. However, when there
are two disulfoxides as with d s - R u C l 2 ( B E S E ) 2 , the sulfoxides are all S-bound. A
stereochemical review of R u bis(disulfoxide) complexes suggests this could be due to lower
14
strain energies for S,S-bonding in a disulfoxide with respect to mixed S,0-bonding. The
R u - 0 bond lengths, in both c w - R u C l 2 ( D M S O ) 2 ( B E S E ) and c w - R u C l 2 ( D M S O ) 4 , are 2.169(3)
and 2.142(3) A, respectively, both significantly shorter than the Ru-S lengths, as expected for
a stronger interaction between the O-atom and the Ru than between the S-atom and the Ru.
The bond angles in all three complexes show a distorted tetrahedral geometry about
the S-atom, with the C - S - C angles being shorter (97.5-100°) in all cases than the C - S - 0 angle
(103-109°), because of the S-0 double bond repulsion interaction with the lone-pair on the S-
atom (Section 3.1.1). The geometry around the Ru is distorted octahedral with cis angles
between 89.1-91.6(9) A, and trans angles between 175.9(5)-179.0(1) A.
46 References on page 75
Chapter 3
Table 3.1 Selected Bond Lengths (A) for d s - R u C l 2 ( D M S O ) 2 ( B E S E ) , cis-R u C l 2 ( D M S O ) 4 , and c w - R u C l 2 ( B E S E ) 2 .
Bond d s - R u C l 2 ( D M S O ) 2 ( B E S E ) d s - R u C l 2 ( D M S O ) 4
a d s - R u C l 2 ( B E S E ) 2
b
S-O (DMSO) 1.474(4) 1.483, 1.485(5) -
S-O (DMSO) 1.529(3) 1.557(4) -
S-O (BESE) 1.471, 1.474(3) - 1.470- 1.479(2)
S-C (BESE) 1.792(6)- 1.809(5) - 1.796- 1.814(3)
S-C (DMSO) 1.762, 1.778(5) 1.783 - 1.808(6) -
S-C ( D M S O ) 1.780, 1.782(5) 1.783, 1.793(6) -
Ru-Cl 2.428, 2.434(1) 2.435(1) 2.422 - 2.449(8)
Ru-S (DMSO) 2.283(l) c 2.276,, 2.277(l) c -
2.252(l) d
Ru-S (BESE) 2.214(l) d - 2.271 - 2.274(8)c
2.250(l) c 2.297 - 2.308(8)d
R u - 0 (DMSO) 2.169(3 ) e 2.142(3) e -
a Data taken from ref. 12. b Data taken from ref. 30, 3 1 . c Trans to C l . d Trans to O. e Trans to S.
47 References on page 75
Chapter 3
Table 3.2 Selected Bond Angles (°) for c w - R u C l 2 ( D M S O ) 2 ( B E S E ) , c w - R u C l 2 ( D M S O ) 4 , and c w - R u C l 2 ( B E S E ) 2 .
Bond Angle c w - R u C l 2 ( D M S O ) 2 ( B E S E ) c w - R u C l 2 ( D M S O ) 4
a c w - R u C l 2 ( B E S E ) 2
b
C-S-O ( D M S O ) 105.8, 106.3(2) 106.3(3) - 107.7(4) -
C - S - 0 ( D M S O ) 103.1, 105.1(2) 104.6, 104.2(3) -
a Data taken from ref. .2. b Data taken from ref. 30,31.
Relevant IR data are given in Table 3.3. The IR of c w - R u C l 2 ( D M S O ) 2 ( B E S E ) shows
two bands at a lower frequency than seen for free D M S O (1055 cm" 1), the one of larger
intensity at 926 cm" 1 is assigned to D M S O , and the other at 996 cm" 1 is assigned to the methyl
rocking frequency (cf. pr = 970 - 1024 cm"1 for cz ' s -RuCl 2 (DMSO) 4
3 3 ) . The bands at 1029
and 1135 cm"1 are assigned to S-bound B E S E , and the band at 1101 cm" 1 is assigned to
D M S O . The O-bound sulfoxide shows the characteristic shift to a lower frequency compared
with that of free ligand, while S-bound sulfoxide shows a shift to a higher frequency, as
expected (Sections 3.2.1 and 3.2.2).
48 References on page 75
Chapter 3
Table 3.3 The S-O stretching frequency values for c w - R u C l 2 ( D M S O ) 2 ( B E S E ) , cis-R u C l 2 ( D M S O ) 4 , d s - R u C l 2 ( B E S E ) 2 , and for free D M S O and B E S E . a
Complex Vso (cm"1) Ref. S-bound O-bound
c w - R u C l 2 ( D M S O ) 2 ( B E S E ) 1029,1101,1135 926 tw
c « - R u C l 2 ( D M S O ) 4
b 1086,1108 927 34
c w - R u C l 2 ( B E S E ) 2 1092, 1122; 1128 - 31,32
B E S E 1019; 1015 - 15,32
D M S O b 1055 - 1
a In K B r , unless stated otherwise. In Nujol.
The proposed solution behaviour for c / s -RuCl 2 (DMSO) 2 (BESE) (I) is shown in
Figure 3.3. The ' H - N M R spectrum in D 2 0 of (I) immediately upon dissolution shows a
singlet in the region of that for free D M S O at 8 2.60 which is due to displacement of the O-
bound D M S O by D 2 0 (the addition of D M S O to the N M R sample resulted in an increase of
the signal at 8 2.60). A multiplet at 8 1.37 consists of unresolved triplets which correspond
to the methyl groups of the B E S E ligand in different environments. The assignments of the
triplets are further hindered by the presence of another species (IV) formed by chloride-water
exchange (see below).
49 References on page 75
Chapter 3
H 2 O | „„0H 2
1
Figure 3.3 The proposed aqueous solution behaviour of czs -RuCl 2 (DMSO) 2 (BESE) .
The multiplet ranging from 8 3.4 - 3.8 represents the C H 2 protons on the backbone
and arms of the B E S E ligand, and could not be further assigned. The singlets at 8 3.08, 3.16,
3.17, 3.21 are thought to represent the protons of the S-bound D M S O . The peaks at 8 3.08,
and 3.21 are assigned to the methyl groups of the D M S O in (U). The relatively small singlet
at 8 3.17 is assigned to the methyl groups of the D M S O in the cationic complex (IV); a
singlet is observed because (IV) contains a plane of symmetry. This suggests that a small
amount of (IV) is formed immediately upon dissolution of (I) while none of (HI) is formed
indicating krv > k m . Of note, there is an unassigned peak (?) slightly downfield of the peak
at 8 3.17 which may be due to another isomer in solution.
After 24 h, the N M R spectrum changes considerably (Figure 3.4) and two new
singlets at 8 3.11 and 3.22 arise along with corresponding decreases of the signals at 8 3.08
50 References on page 75
Chapter 3
and 3.21; these changes are attributed to conversion of (U) into complex (UJ). As well, the
singlet at 8 3.17 becomes larger due to further conversion of (U) into (IV).
rv
' rv
m in
I I j I I I I | I I I I | I I I I | I I I I | I I M | I I I I | I I I I | I I I I | I I I I | I I I I | I I I I | I I I I | I I I I | I I I
Figure 3.4 Variation of the 1 H - N M R spectra, in D 2 0 , of R u C l 2 ( D M S O ) 2 ( B E S E ) with time; (A) immediately upon dissolving the complex in H 2 0 , and (B) 24 h after dissolving the complex in H 2 0 .
The proposed solution behaviour of d s - R u C l 2 ( D M S O ) 2 ( B E S E ) is analogous to that of
34
c w - R u C l 2 ( D M S O ) 4 in H 2 0 (Chapter 1, Section 1.3.1), and is supported by conductivity
data showing the conductivity, in H 2 0 , increases to a steady maximum value of 103 Q" 1 2 1 cm mol" after 6.5 h (Figure 3.5). This suggests that in solution (II) slowly changes from a
35 neutral species to a 1:1 electrolyte system. The conductivity at 37 °C increases to 110 £2"
1 9 1
cm mol" after only 2 h of dissolution of (I) (Figure 3.5).
51 References on page 75
Chapter 3
120
o •o c o
• •
O 0 0 100 200 300 400 500 600
Time (minutes)
Figure 3.5 Variation of the conductivity measurements of c /s -RuCl 2 (DMSO)2 (BESE)
with time in H 2 0 at 25 °C ( • ) , in 3 m M NaCI at 25 °C (• ) , and in H 2 0 at 37 °C (-).
The conductivity of cz 's-RuCl 2 (DMSO) 2 (BESE) was also followed at 3 m M and
150 m M concentrations of NaCI to show the behaviour of the complex under biological
conditions. At 3 m M NaCI (intracellular concentrations), the conductivity increased to a
steady maximum value of 102 f X ' c n ^ m o l ' 1 after 6 h, following essentially the same rate as
that of the complex in H 2 0 (Figure 3.5). It is thought the dissociation of chloride is inhibited
at 150 m M NaCI (extracellular concentrations); however, the conductivity measurements at
this concentration are not conclusive because the conductivity of the species present is likely
masked by that of NaCI. If chloride dissociation is inhibited, c w - R u C l 2 ( D M S O ) 2 ( B E S E )
could act biologically by diffusing across the cellular membrane, because in an extracellular
(150 mM) environment the complex wi l l remain the neutral species (II). Once inside the
cell, at a [Cl"] of 3 m M , the dissociation of chloride gives conversion to the cationic
complexes (HI) and (IV). Observation of the conductivity over 24 h (for each treatment)
52 References on page 75
Chapter 3
shows the second chloride does not dissociate. Of note, a conductivity study of cis-
34 RuCl2(DMSO)4, at a [Cl] of 150 mM, shows complete inhibition of chloride dissociation.
The plots of ln(AM D - A M t ) versus time give straight lines, thus showing a first-order
dependence for the dissociation of Cl" from cw-[RuCl2(DMSO)(BESE)H20] (Figure 3.6). At
25 °C, k o b s is 7.8 x 10"3 min"1 (ti / 2 is 89 min) and, at 37 °C, k o b s is 3.4 x 10"2 min"1 (t1/2 is
20 min), showing the rate of dissociation is ~ 4.5 times faster at biological temperatures
(where k o b s = k m + krv; Figure 3.3). Of note, the conductivity intercepts are slightly different
due to the errors involved with the time needed to dissolve the complex and to stabilize the
temperature before the first conductivity measurement was taken.
Figure 3.6 A plot of In (A M ~ - A M t ) [where A M ° o is the maximum conductivity value and A M t is the conductivity at time (t)] versus time for cz's-RuCl^DMSO^BESE) in H 2 0 at
25 °C (•), and in H 2 0 at 37°C (-).
53 References on page 75
Chapter 3
Cw-RuCi2(DMSO)2(BESE) was tested in vitro for cytotoxicity on Chinese hamster
ovarian cells, and for anti-cancer activity on mammalian breast cancer cells, and the results
are presented in Chapter 4.
Another method for synthesizing cw-RuCl 2(DMSO) 2(BESE), but in lower yield,
involves refluxing cw-RuCl2(DMSO)4 for 3 h with 1 equivalent of B E S E . It should also be
noted that using 2 equivalents of B E S E in this method results in the isolation of cis-
RuCl 2 (BESE) 2 . Attempts to replace the B E S E ligand in c « - R u C l 2 ( B E S E ) 2 using
stoichiometric amounts of DMSO were unsuccessful and resulted in isolation of the starting
material.
3.3.2 [RuCl(BESE)(H20)]2(lii-Cl)2 with BESP, and with BPSP
Refluxing [RuCl (BESE)(H 2 0 ) ] 2 f>Cl ) 2 with 2 equivalents of B E S E results in the
32
isolation of rra«^>-RuCl2(BESE)2 as shown by Cheu. In attempts to synthesize mixed
sulfoxide complexes, [RUC1(BESE)(H20)]2(/J-C1)2 was reacted with BESP and with BPSP;
however, cw-RuCl 2(BESE) 2 was obtained by crystallization of the reaction product from
aqueous solution. An electrospray mass spectrum of [RuCl(BESE)(H20)]2(iu-Cl)2 in aqueous
solution was performed to determine if the complex remains dinuclear in solution. Peaks at
709 [M + - Cl], 690 [M + - Cl - H 2 0 ], and 672 [M + - 2C1] suggest that the dimer does not
dissociate to monomer. As well, after [RuCl(BESE)(H20)]2(jU-Cl)2 is refluxed in H2O, the
complex is isolated unchanged.
Previous work has shown that [RuCl(BESE)(H20)]2(AJ-Cl)2 is a 2:1-3:1 electrolyte in
H 2 0 , and titration with NaOH showed that two equivalents of base were required for 1
equivalent of [RuCl(BESE)(H20)]2(^-01)2, suggesting that two equivalents of Cl" and two
54 References on page 75
Chapter 3
32 equivalents of H + are liberated on dissolving the dimer in water. It appears the complex in
solution perhaps exchanges the terminal chlorides for H2O and becomes
[Ru(BESE)(OH)(H 2 0) ] 2 (>Cl ) 2 . That cw-RuCl 2(BESE) 2 is formed on refluxing the dimer
with BESP (and with BPSP) is surprising, but clearly the monomer is formed slowly from the
hydroxy species. It is not clear, however, why there is no interaction with the added
disulfoxides as there is interaction with additional BESE to give frarcs-RuCl 2(BESE) 2.
Possibly the BESE complex is thermodynamically more stable than a mixed disulfoxide
complex such as RuCl 2(BESE)(BESP). Of note, the 1 H-NMR spectrum in D 2 0 of cis-
RuCl 2 (BESE) 2 has signals which correspond to those of the free ligand indicating that one of
the BESE ligands dissociates (Section 2.10.3). As well, the singlet seen at 8 3.75, which
could only be from a complex with equivalent methylene groups on the backbone of the
ligand, suggests that cw-RuCl 2 (BESE) 2 may isomerize in aqueous solution to the trans
isomer.
3.4 Ruthenium Thioether Complexes
Complexes such as R u X 3 ( L ) 3 (L = DMS or TMS and X = Cl or Br) have been
isolated from reactions of ruthenium with acidified DMSO and T M S O . 1 3 ' 3 6 The reactions
were performed at higher temperatures (130 - 140 °C) than used for the formation of the
The mononuclear, dithioether Ru complexes zr<ms-RuCl2(BCyTE)2-2 H 2 0 (BCyTE =
l,2-bis(cyclohexylthio)ethane) and frans-RuCl2(BPhTE)2 (BPhTE = 1,2-
bis(phenylthio)ethane), and dinuclear dithioether complexes of the formula [RuCl2(L)]2(,u-
Cl) 2 with L = l,3-bis(ethylthio)propane (BETP), l,3-bis(propylthio)propane (BPTP), 1,3-56 References on page 75
Chapter 3
bis(butylthio)propane (BBTP) , and l,3-bis(pentylthio)propane (BPeTP), have been
3 2
synthesized in this laboratory. The goal of synthesizing these thioether complexes was to
determine their geometry, and then oxidize the coordinated thioether using a reported 41
procedure with dimethyl dioxirane to see i f the geometry was retained. This would create a
method to synthesize R u complexes that have not otherwise been obtained by direct reaction
of ruthenium and sulfoxide. A stereochemical study on Ru(disulfoxide) complexes indicates
the cis isomers are more stable than the trans isomers, and therefore the trans complexes may 14
not be obtained by reacting R u precursors with sulfoxide. However, f rans-RuCl 2 (DMSO )4
was shown to be more biologically active, because of its aqueous solution chemistry (Chapter 34
1), than the cis isomer, and the rran.y-Ru(disulfoxide) complexes were shown to accumulate
in cells and to bind D N A to a greater degree than the cis isomers (Chapter 4) making the 30,31
trans isomers the preferred products. If isolation of a trans complex cannot be achieved 3 2
by reacting a R u precursor with sulfoxide, as with formation of c /5 , -RuCl 2 (BCySE) 2 , it 32
might be accessible by reacting Ru with the thioether, as with rnms-RuCl 2 (BCyTE) 2 -2 H 2 0 ,
followed by oxidation of the coordinated thioether. Work in this thesis isolated the thioether
complex r ra«5 -RuCl 2 (BPTP) 2 (see below).
3.4.1 Trans-RuCl2(BPTP)2
In an attempt to synthesize the dinuclear complex [RuCl 2 (BPTP)] 2 ( /z-Cl) 2 using the
32
method by Cheu (in air) and under N 2 , r rans-RuCl 2 (BPTP) 2 was isolated. The ' H - N M R in
CDCI3 shows a triplet at 8 1.02, which corresponds to the C H 3 groups of B P T P ; one triplet is
seen because all the CH3 groups are magnetically equivalent. The multiplet seen at 8 1.67 is
57 References on page 75
Chapter 3
assigned to the CH2 group adjacent to the methyls. The multiplet at 8 2.28 is assigned to the
C H 2 protons on the central carbon of the ligand backbone, and the two broad singlets at
8 2.79, and 8 2.90 correspond to the CH2 groups next to the S-atoms. Tentatively, the peaks
at 8 2.79 and 2.90 are assigned to the C H 2 protons on the arms of the ligand and those on the
backbone, respectively. The ' H peaks become more resolved as the CDCI3 solution of the
complex is warmed from 213 to 313 K (Figure 3.8). Elemental analysis also shows that the
species isolated is the mononuclear complex and not the previously isolated and structurally
32
characterized [RuCl2 (BPTP)]2 (^-0 )2 . The synthetic work indicates a possible solvent
effect because the analyzed crystals of rrarcs-RuCl2(BPTP) 2 (found to be twinned by X-ray
crystallography) were grown from acetone/Et 20, whereas crystals of the dinuclear species
were grown from CH2CI2. Attempts in this work to isolate crystals from C H 2 C 1 2 were
unsuccessful.
3 1 3 K
98 K
I . . . . I . 1 . 1 j . . . . I 1 1 . . I
3 . 0 2 . 5 2 . 0 1 . 5 1 . 0
Figure 3.7 1 H - N M R spectra of rran5-RuCl 2 (BPTP) 2 in C D C 1 3 , showing an increase in resolution with temperature.
58 References on page 75
Chapter 3
3.5 Ruthenium Sulfoxide-Bridged Complexes
D M S O can bridge Ru centres as shown by the two structures [Ru2(jU-Cl)(^-H)(^-
D M S 0 ) C l 2 ( D M S 0 ) 4 ] - 2 C H 2 C 1 2
4 2 and [ R u a G u - C l X ^ - D M S O ^ ^ D M S O M C O y , 4 3 where
the bridging D M S O is necessarily both S- and O-bound. The S-0 bond lengths for the
bridging D M S O are 1.532(4) and 1.508(5) A, respectively, which are closer to the S-O bond
lengths of O-bound than S-bound sulfoxide (Section 3.2.2). The S-O bond lengths for the S-
bound D M S O in the complexes range from 1.442 to 1.486 A as expected (Section 3.2.1). A
trinuclear complex [Ru 3 (p -MPSO-S ,0 ) 2 Gu-Cl ) 4 (MPSO-S) 4 Cl 2 ] ( M P S O = methyl phenyl
9 44
sulfoxide) with bridging M P S O has an S-O bond length for the ^u-MPSO of 1.507(5) A.
Complexes of Sn, Cu , and Pt with bridging disulfoxides have also been synthesized.
Carvalho et al. characterized catena-poly{cis-Cl2-tran5-(CH3) 2Sn(rV)](jU-0,0'-meso-BPSE)
which has two O-bound B P S E ligands at one Sn centre and each bridges another Sn centre
(Figure 3.7). The average S-O bond length is 1.520(3) A, which is consistent with O-bound 45
sulfoxide. Filgueiras et al. have characterized another Sn complex with a bridging
disulfoxide, [SnCl-cw-Ph3]2(^-0,0'-rac-l,2-bis(n-propylsulfinyl)ethylene), where the 46
disulfoxide bridges two Sn centres. The structure shows the sulfoxide to be O-bound with
an S-O bond length of 1.488(6) A, which is closer to an S-O bond length for S-bound
sulfoxide. Geremia et al. have characterized a Cu structure of the formula
[Cu(BPSP) 2 (C10 4 ) ] n
n + with the Cu-atoms bridged by O-bound B P S P ; the S-O bond length is 5 47
1.533(5) A as expected for O-bound sulfoxide. Two structures with bridging meso-BPhSE
have been reported. The first, [SnClPh 3 ] 2 ( i u-BPhSE), was characterized by Zhu et al. and has 19
an S-O bond length of 1.525(4) A , supporting the observed O-bound sulfoxides. The
59 References on page 75
Chapter 3
second is [PtCl 2(PEt 3)] 2(At-S,S meso-BPhSE), shown in Figure 3.7; this has S-bound
o 48 sulfoxides and an S-O bond length of 1.475(9) A , consistent with the S-bound sulfoxides.
C l
+ C H 2 S
Pr Pr E t 3 P — P t — C l O I II
P h — S — C H 2 — C H 2 — S Ph
CP J n O C l — P t — P E t 3
Cl
(1) (2)
Figure 3.8 The structures of catena-poly{cz'i'-Cl2-rran5-(CH 3) 2Sn(IV)]( Ja-0,0'-me50-BPSE) and [PtCl 2 (PEt 3 ) ] 2 ( / i -S,S meso-BPhSE).
In this thesis work, the bridging B P h S E complex [RuCl 3 (BPhSE)] 2 ( J u-BPhSE)x H 2 0
was isolated; IR data suggest the sulfoxide is S-bound (Section 3.5.1). As well , two p-
cymene complexes with S-bound bridging sulfoxides were synthesized: [RuCl 2 (p-
cymene)] 2( )u-BESE) with S-bound sulfoxides has been structurally characterized, and the
analogous complex [RuCl 2(p-cymene)] 2( iu-BESP) was also made (Section 3.6.1).
3.5.1 [RuCl3(BPhSE)]2(lA-BPhSE)x H20
[RuCl 3 (BPhSE)] 2 Gu-BPhSE)-x H 2 0 was prepared by various methods
(Section 2.7.1). The 1 H - N M R data show a paramagnetic complex, and repeat elemental
analyses support the formulation shown with one or two water molecules. The IR stretches
1070, 1082, 1105, and 1116 cm"1 suggest S-bound sulfoxide when compared with the values
32
for free B P h S E (1035, 1089 cm"1), and no bands are seen in the region of O-bound
sulfoxide. The mass spectrum shows peaks at 1142 [ M + - 3 C l ] , and 972 [ M + - BPhSE] . The
60 References on page 75
Chapter 3
complex was non-conducting in C H 2 C 1 2 (0.6 i2" 'cm 2 mor 1 ) , 4 9 while the yellow solid
dissolved in D M S O to give f rans-RuCl 2 (DMSO) 4 as shown by 1 H - N M R data.
3.6 Introduction to Rutheniump-Cymene Complexes; p-cymene = p-isopropyltoluene
Ruthenium arene complexes have shown promising results in catalytic hydrogenation
of olefins, ketones, and arenes, and such complexes with ancillary chiral chelating
50
diphosphine ligands have been studied as potential asymmetric hydrogenation catalysts.
Mashima et al. have structurally characterized a cationic, dinuclear Ru(IJ) complex triply-
bridged by the S-atoms of benzenethiolate ligands ([Ru 2(SPh) 3(p-cymene) 2] +). 5 1 A Ru(p-
cymene) complex with a chelating sulfoxide carboxylate ligand, [Ru(p-cymene)(L)Cl],
where L = (/?)-2-[(i?)-phenylsulfinyl]propionate that binds as shown in Figure 3.9, has been 52
synthesized and structurally characterized for catalytic use. The S-O bond length of o
1.478(2) A is as expected for the S-bound sulfoxide.
61 References on page 75
Chapter 3
Figure 3.9 Structures of (1) (/?)-2-[(R)-phenylsulfinyl]propionate, indicating the stereogenic centres (*), and the metal binding sites (—>) (adapted from ref. 52), and (2) [Ru(ade)(ri6-/?-cymene)]4(CF3S03)4 (taken from ref. 53).
6 5 3 6 Other arene complexes such as [(r| -CeFf^RuC^metro)] and [RuCl 2 (r | -
54
C6H 6 ) (DMSO)] have been synthesized and studied for topoisomerase II activity and D N A
damage ability, respectively. Korn and Sheldrick have shown that reaction of [RuCl 2 (p-
cymene)] 2 Gu-Cl 2) with adenine in the presence of Ag(CF 3 S03) forms [Ru(ade)(r|6-/7-
cymene)] 4(CF 3S03)4 (Figure 3.9) that shows the ability of Ru(p-cymene) complexes to
interact with D N A bases. 5 5 Most recently, and after the jU-BESE complex had been
synthesized (see below), [Ru(r|6-/?-cymene)Cl2(pta)] has been structurally characterized and 56
shown to exhibit pH-dependent DNA-binding (Chapter 1). A s well , half-sandwich Ru(U)
arene complexes containing nitrogen ligands have been patented for the treatment of
cancer. 57
In this thesis work, novel [RuCl 2(p-cymene)] 2(/i-disulfoxide) complexes (disulfoxide
= B E S E and B E S P ) were synthesized and characterized. The complex [RuCl 2 (p-
62 References on page 75
Chapter 3
cymene) ]2( jU-BESE) is the first structurally characterized bridging disulfoxide R u species
known. Both disulfoxide bridged complexes are water-soluble, as is the starting material,
[RuCl(/7-cymene)] 2 (^-Cl) 2 , which in aqueous solution becomes {[Ru(p-
58
cymene)](/ i-Cl) 3 }Cl. A third water-soluble complex [RuCl(p-cymene)(BESE)]PF 6 was
also synthesized and structurally characterized.
3.6.1 [RuCl2(p-cymene)]2(/J.-BESE) and [RuCl2(p-cymene)]2(/a-BESP)
[RuCl2Gj?-cymene)]2(jU-BESE) was synthesized by reacting [RuCl(p-
cymene)] 2( iti-Cl) 2 with B E S E in C H 2 C 1 2 under N 2 . The precipitated red complex needed no
purification. IR bands at 1082 and 1110 cm"1 support S-bound sulfoxide. Crystals of the
complex suitable for X-ray analysis were grown by slow evaporation of a C H 2 C 1 2 solution of
the complex. The O R T E P diagram (Figure 3.10) shows bridging S-bound meso-BESE with
5-chirality at S ( l ) and 7?-chirality at S(2). The r|6-/?-cymene ligands (one at each Ru) are syn
with the isopropyl groups pointing in different directions. Selected bond lengths and bond
angles of [RuCl 2 (p-cymene)] 2 ( / i-BESE), [RuCl(p-cymene)(BESE)]PF 6 , and
[PtCl 2(PEt 3)] 2(A*-S,S meso-BPhSE) are given in Table 3.4. The S-0 bond lengths for the title
complex (1.476(2) and 1.483(2) A) are consistent with S-bound sulfoxide, and are similar to
the S-0 length of 1.475(9) A seen in [PtCl 2 (PEt 3 )] 2 (^-S,S meso-BPhSE). The Ru-S bond
lengths of 2.335(7) and 2.345(7) A are just shorter than the sum of the covalent radii of Ru
o 1
and S (2.37 A ) , suggesting very little 7t-back-donation between the Ru- and S-atoms. The
sulfoxide has a distorted trigonal pyramid geometry with C-S-C angles of 100.2 and
102.5(1)°, and C-S-O angles of 103.9 - 108.4(1)°
63 References on page 75
Chapter 3
C(7)
R U ( I ;
C(3)
C(4)
C(ll) C(5)
Cl(2) C(12)
C(13) C(10)
Figure 3.10 A molecular structure representation (ORTEP) of [RuCl 2(p-cymene)]( iu-BESE) with 50% probability thermal ellipsoids shown; H-atoms are omitted for clarity (a stereoview and crystal data are given in Appendix 2).
64 References on page 75
Chapter 3
Table 3.4 Selected Bond Lengths (A) and Bond Angles (°) for [ R u C l ^ - c y m e n e ) ] ^ -B E S E ) , [RuCl(p-cymene)(BESE)]PF 6 , and [PtCl 2 (PEt 3 ) ] 2 i>S,S meso-BPhSE)
C - S - 0 103.9- 108.4(1) 107.0- 109.1(2) 107.2-110.4(5)
C-S-C 100.2, 102.5(1) 101.0, 103.3(2) 97.9(5)
Cl-Ru-S 85.70 - 86.23(3) 87.37, 89.40(4) -
Ru-S-0 115.4(1), 114.15(9) 115.3, 118.1(1) -
a Data are taken from the structural conformer shown in Figure 3.15 (see below), although the angles and bonds are very similar for both conformers. b The schematic structure is shown in Figure 3.7, and the data are taken from ref. 48.
The ' H - N M R spectrum for [RuCl 2 (p-cymene)](jU -BESE), in C D C 1 3 at r.t., gives
distinct peaks at 8 1.26 (d), 2.14 (s), 2.90 (sp), 5.31 (d), and 5.44 (d) which correspond to
those of the p-cymene precursor material [RuCl(p-cymene)] 2( iu-Cl) 2. There are also
downfield shifted peaks, corresponding to the coordinated p-cymene protons of the p - B E S E
complex. The doublet at 8 1.28 represents the C H 3 protons (5) of the isopropyl group on the
p-cymene, and the septet at 8 3.05 corresponds to the C H proton (4) of the isopropyl group
(Figure 3.11). The aromatic protons (3, 2) are seen as broad singlets at 8 5.55 and 5.63,
respectively, and the singlet at 8 2.27 is due to the C H 3 group (1) on the p-cymene.
65 References on page 75
Chapter 3
1-5
Figure 3.11 The structure of p-cymene showing the ^ - N M R spectra designations. 1 = methyl group protons (s), 2, 3 = aromatic protons (d), 4 = C H proton of the isopropyl group (sp), 5 = methyl protons of the isopropyl group (d).
The peak at 8 1.36 (t) is assigned to the C H 3 groups on the B E S E ligand; however, it
is unclear whether this is for free or bridging B E S E because only one triplet is seen; the two
'expected' triplets may be superimposed. The broad peaks at 8 2.82 (bs), and 3.21(bs) are
difficult to assign, but likely correspond to the C H 2 protons of bridged or free B E S E .
Figure 3.12 shows the variable temperature ' H - N M R spectra for the region 8 2.0 -
4.5. Of note, only one triplet at ~ 8 1.36 is seen, at all the temperatures shown, for the C H 3
region of the B E S E suggesting, as mentioned above, that the signals for free and bridging
B E S E are superimposed. As the solution is cooled to 243 K the singlet at 8 2.27 for the fx-
B E S E complex becomes larger and the peak for the R u precursor diminishes. The peaks in
the 8 2.5 - 4.0 region also become more resolved and the doublets seen at 8 3.35 and 4.05 are
assigned to the diastereotopic C H 2 protons on the ligand backbone of ^u-BESE. The
multiplets at 8 2.75 and 3.62 are assigned to the C H 2 groups on the arms of the ligand.
66 References on page 75
Chapter 3
2 7 3 k
2 8 3 k
3 1 3 K
4 . 0 3 . 5 3 . 0 2 . 5 2 . 0 ppm
Figure 3.12 The ' H - N M R spectra for [RuCl 2(p-cymene)] 2(//-BESE) in C D C 1 3 at various temperatures from 243 to 313 K , showing that as the temperature decreases the 1 H - N M R signals become more resolved.
Adding one equivalent of B E S E to [RuCl 2(y>cymene)] 2(//-BESE) in C D C 1 3 does not
region from 8 2.0 - 6.0 is shown), adding two equivalents of B E S E causes the peaks
corresponding to the / ^ - B E S E complex to become more predominant. This is exemplified by
the singlet at 8 2.27 and the broad signals at 8 5.55 and 5.63 increasing in intensity and the
corresponding signals for the R u precursor decreasing. A t the same time, the peaks
corresponding to those o f free B E S E , at 8 1.36 and from 5 2.90 to 3.30, intensify.
change the r.t. H - N M R spectrum significantly. However, as shown in Figure 3.13 (only the
67 References on page 75
Chapter 3
JUl
5.5 -i | r-5 . 0 4 • 5 4.0 3.5 3.0 2.5 2.0 ppm
Figure 3.13 The r.t. ' H - N M R spectra in C D C 1 3 for (A) [RuCl 2(p-cymene)] 2(//-BESE) with one equivalent of B E S E , (B) with 2 equivalents of B E S E , and (C) with excess B E S E .
The data suggest equilibrium behaviour such as in eq. 3 for [RuCl 2 (p-cymene)] 2 0
B E S E ) in C D C 1 3 . The 1 H - N M R experiments indicate that adding B E S E and lowering the
temperature favour the left hand side of the reaction.
CDC13
[RuCl 2(p-cymene)] 2(//-BESE) ^==* [RuCl(p-cymene)] 20-Cl) 2 + B E S E (3)
The [RuCl(p-cymene)] 2(//-Cl) 2 starting material for the synthesis of [RuCl 2 (p-
cymene)] 2 (//-BESE) dissolves in water to form the cationic complex {[Ru(p-cymene)]2(//-
C1)3}C1. The ' H N M R spectrum in D 2 0 shows a doublet at 8 1.19 and septet at 6 2.73 for
the p-cymene protons 5 and 4, respectively. A singlet at 8 2.06 corresponds to the /?-cymene
protons 1, and the doublets at 5 5.48 and 5.70 represent the aromatic protons 3 and 2,
respectively. There are also small signals shifted slightly downfield within each of the p-
cymene proton regions which suggests a small amount of another isomer. The proposed
68 References on page 75
Chapter 3
aqueous solution behaviour for [RuCl 2 (p-cymene)] 2 (//-BESE) is presented in Figure 3.14;
the ' H - N M R suggests the complex may dissociate to {[Ru(p-cymene)] 2(>Cl)3}Cl and B E S E
before forming the cationic complex [RuCl(j>cymene)(BESE)]Cl.
Figure 3.14 The proposed aqueous solution behaviour of [RuCl 2 (p-cymene)] 2 (>-BESE) and the subsequent formation of [RuCl(p-cymene)(BESE)]PF 6 with the addition of N H 4 P F 6 .
When [RuCl 2 (p-cymene)] 2 ( / a-BESE) is dissolved in H 2 0 , the ' H N M R shows signals
at 8 1.17 (t), 2.84 (m), 3.13 (m) which are those for free B E S E ligand. A s well , observed
peaks at 8 1.07 (d), 1.40 (t), 2.06 (s), 2.71 (sp), 3.40-3.65 (m), 6.29 (s) correspond to those of
[RuCl(p-cymene)(BESE)]Cl (cf. ' H - N M R data of the characterized [RuCl f>
cymene)(BESE)]PF6 complex discussed in Section 3.6.2). Small peaks seen for {[RuOp-
cymene)] 2(//-Cl) 3}Cl disappear with time. If [RuCl(p-cymene)] 2(/y-Cl) 2 is placed in water
69 References on page 75
Chapter 3
and then B E S E is added, the 1 H - N M R spectrum shows small peaks for free B E S E which
disappear over time, peaks for [RuCl(p-cymene)(BESE)]Cl, and small peaks for {[Ru(p-
cymene)]2(//-Cl)3}Cl. The water-soluble p - B E S E complex was tested in vitro for
cytotoxicity on Chinese hamster ovarian cells and for anti-cancer activity on mammalian
breast cancer cells (Chapter 4).
[RuCl2(p-cymene)]2(/^-BESP) was prepared using the same method as for synthesis
of [RuCi2(p-cymene)]2(//-BESE). The structure is assumed to be analogous to that of
[RuCl 2 (p-cymene)] 2 (/ /-BESE). The ! H N M R spectra for [RuCl2(p-cymene)]2G"-BESP)
shows peaks corresponding to the p-cymene protons of the R u precursor, and peaks for the
5.63 (bs); the 'extra' peak at 5 2.35 is due to the 'extra' C H 2 group on the backbone of the
ligand. Several IR bands (1074, 1082, 1090, 1095, 1108, 1116, 1122 cm"1) suggest S-bound
sulfoxide.
A n attempted synthesis of [RuCl2(p-cymene)]2C"-BPhSE) using the same method
noted above resulted in isolation of the starting materials.
3.6.2 [RuCl(p-cymene)(BESE)]PF6
[RuCl(p-cymene)(BESE)]PF 6 was synthesized by dissolving [RuCl(p-
cymene)]2(//-Cl)2 and B E S E in water (under N2 or air) to give a yellow solution, and then
adding NH4PF6, or by dissolving [RuCl2(p-cyrnene)]2(//-BESE) in water to give a yellow
solution and adding NH4PF6. Isolation of the product in both cases was by crystallization
from a concentrated aqueous solution of complex. X-ray quality crystals were grown from
slow evaporation o f a 1:1 H20/MeOH solution of the complex. The O R T E P structures of the
70 References on page 75
Chapter 3
two conformers found in the asymmetric unit are shown in Figures 3.15 and 3.16. The
structure in Figure 3.15 shows a cationic complex, with a PF6 counterion (omitted for
clarity), with one S-bound meso-BESE (the chirality at S ( l ) is R and at S(2) is S) which is
adjacent to the non-isopropyl CH3 group of the r)6-p-cymene. The other conformer (Figure
3.16) shows a similar structure with one maso-BESE (the chirality at S(3) is S and at S(4) is
R) in close proximity to the isopropyl group. Selected bond lengths are shown in Table 3.4.
The data for both conformers are very similar and therefore only those for the conformer
shown in Figure 3.15 are discussed. The S-0 bond lengths of 1.461(3) and 1.467(3) A are
consistent with S-bound sulfoxide. The Ru-S bond lengths of 2.288(1) and 2.302(1) A are
shorter then those seen in the bridged [RuCl 2 ^-cymene)] 2 ( / / -BESE) complex indicating a
higher degree o f 7t-back-bonding between the R u and the S-atom. The C-S-C angles are
101.2 and 103.3(2)°, and the C-S-O angles are 107.0-109.1(2)°, as expected for a distorted
trigonal pyramid geometry about the S-atom.
The 1 H - N M R spectrum in D 2 0 shows one triplet at 5 1.40 for the CH3 groups o f the
B E S E revealing they are equivalent and indicating the molecule is fluctional in solution. A
multiplet at 5 3.40-3.70 corresponds to all the C H 2 protons of the B E S E ligand, but cannot be
further assigned. The doublet at 8 1.06 and the septet at 8 2.70 correspond to the p-cymene
protons 4 and 3, respectively. The singlet at 8 2.06 corresponds to the p-cymene protons 1,
and the singlet at 8 6.28 must correspond to the aromatic protons 2, yet it is not clear why a
singlet is seen. A singlet was also seen for the aromatic protons of p-cymene complexes of
the formula RuX 2 (p-cymene)(A) ( X = C l , A = P B u n
3 , P M e 2 P h , A s M e 2 P h ; and X = B r or I, A
58
= PBu" 3 ) . The IR data show stretching frequencies at 1072, 1090, 1107, 1119, 1132, 1142
cm"1 consistent with the S-bound sulfoxide; the number of IR bands seen must be due to the
71 References on page 75
Chapter 3
presence of two conformers in the solid state. The conductivity of [RuCl(p-
cymene)(BESE)]PF 6 in H 2 0 is 75 Q^cir^moT 1 which corresponds to a 1:1 electrolyte in
aqueous solution.
Attempts to synthesize and isolate the chloride anion form o f the complex were
unsuccessful; however, it has been identified in situ (Section 3.6.1).
72 References on page 75
Chapter 3
Figure 3.15 A molecular structure representation (ORTEP) of one conformation of [RuCl(p-cymene)(BESE)] + with 50% probability thermal.ellipsoids shown; H-atoms are omitted for clarity (a stereoview and crystal data are given in Appendix 3).
73 References on page 75
Chapter 3
C(19)
Figure 3.16 A molecular structure representation (ORTEP) of a second conformation of [RuCl(p-cymene)(BESE)] + with 50% probability thermal ellipsoids shown; H-atoms are omitted for clarity (a stereoview and crystal data are given in Appendix 3).
74 References on page 75
Chapter 3
References
Davies, J. A . Adv. Inorg. Chern. Radiochem. 1981, 24, 115.
Calligaris, M . ; Carugo, O. Coord. Chern. Rev. 1996,153, 83.
Sze, K . FL; Brion, C. E . ; Tronc, M . ; Bodeur, S.; Hitchcock, A . P. Chem. Phys. 1988,
121, 279.
Viswamitra, M . A . ; Kannan, K . K . Nature 1966, 209, 1016.
Thomas, R.; Shoemaker, C. B . ; Eriks, K . Acta Cryst. 1966, 21, 12.
Bennett, M . J.; Cotton, F. A . ; Weaver, D . L . ; Will iams, R. J.; Watson, W . H . Acta.
Cryst. 1967, 23, 788.
Pearson, R. G . J. Am. Chem. Soc. 1963, 85, 3533.
Farrell, N . A C S Symposium Series; ed. Lippard, S. J., 1983; V o l . 209; p 279.
Turco, A . ; Pecile, C. Nature 1961,191, 66.
Barnes, J. R.; Goodfellow, R. J. Chem. Res., Miniprint 1979, 4301.
McArdle , J. V . ; Schultz, A . J.; Corden, B . J.; Eisenberg, R. Inorg. Chem. 1973,12,
1676.
Mercer, A . ; Trotter, J. J. Chem. Soc. Dalton Trans 1975, 2480.
Yapp, D . T. T.; Jaswal, J. S.; Rettig, S. J.; James, B . R.; Skov, K . A . Inorg. Chim.
Acta 1990,177, 199.
Geremia, S.; Vicentini, L . ; Calligaris, M . Inorg. Chem. 1998, 37, 4094.
Hul l , M . ; Bargar, T. W . J. Org. Chem. 1975, 40, 3152.
75 References on page 75
Chapter 3
(16) Taddei, F. Boll. Sci. Fac. Chim. Ind. Bologna 1968, 26, 107; through ref. 45 in Ch. 3
of E . L . S. Cheu's Ph. D . Dissertation (ref. 32).
(17) Colonna, S., Personal communication to B . R. James; through ref. 46 in Ch . 3 of E. L .
S. Cheu's Ph. D . Dissertation (ref. 32).
(18) Araujo, C. S.; Khiar, N . ; Huxham, L . ; James, B . R. Unpublished data, on-going
collaboration. 2001.
(19) Zhu, F. C ; Shao, P. X . ; Yao, X . K . ; Wang, R. J.; Wang, H . G . Inorg. Chim. Acta
1990,171, 85.
(20) Madan, S. K . ; Hu l l , C . M . ; Herman, L . J. Inorg. Chern. 1968, 7, 491.
(21) Zipp, A . P.; Madan, S. K . Inorg. Chim. Acta 1977, 22, 49, and references therein.
(22) Musgrave, T. R.; Kent, G . D . J. Coord. Chern. 1972, 2, 23.
(23) Khiar, N . ; Fernandez, I.; Alcudia, F. Tetrahedron Lett. 1993, 34, 123.
(24) Tokunoh, R.; Sodeoka, M . ; Aoe, K . ; Shibasaki, M . Tetrahedron Lett. 1995, 36, 8035.
(25) James, B . R.; Morris, R. H . ; Reimer, K . J. Can. J. Chern. 1977, 55, 2353.
(26) James, B . R.; M c M i l l a n , R. S. Can. J. Chern. 1977, 55, 3927.
(27) Alessio, E . ; Balducci, G . ; Lutman, A . ; Mestroni, G . ; Calligaris, M . ; Attia, W. M .
Inorg. Chim. Acta 1993, 203, 205.
(28) Chan, P. K . L . ; Chan, P. K . H . ; Frost, D . C ; James, B . R.; Skov, K . A . Can. J. Chern.
1988, 66, 117.
(29) Chan, P. K . L . ; James, B . R.; Frost, D . C ; Chan, P. K . H . ; Hu , H . - L . ; Skov, K . A .
Can. J. Chern. 1989, 67, 508.
(30) Yapp, D . T. T. Ph. D . Dissertation, University of British Columbia, Vancouver, 1993.
(31) Yapp, D . T. T.; Rettig, S. J.; James, B . R.; Skov, K . A . Inorg. Chern. 1997, 36, 5635.
76 References on page 75
Chapter 3
(32) Cheu, E . L . S. Ph. D . Dissertation, University of British Columbia, Vancouver, 2000.
(33) Evans, I. P.; Spencer, A . ; Wilkinson, G. Chem. Soc., Dalton Trans. 1973, 204.
(34) Alessio, E . ; Mestroni, G . ; Nardin, G. ; Attia, W . M . ; Calligaris, M . ; Sava, G. ; Zor'zet,
S. Inorg. Chem. 1988, 27, 4099.
(35) Huheey, J. E . Inorganic Chemistry (4th ed.): New York, 1993.
(36) Jaswal, J. S.; Rettig, S. J.; James, B . R. Can. J. Chem. 1990, 68, 1808.
(37) Ledlie, M . A . ; A l l u m , K . G . ; Howell , I. V . ; Pitkethley, C. R. J. Chem. Soc. Perkin I
1976, 1734.
(38) Lucas, C. R.; L i u , S.; Newlands, M . J.; Gabe, E . J. Can. J. Chem. 1990, 68, 1357.
(39) Hartley, F. R.; Murray, S. G. ; levason, W. ; Soutter, H . E . ; McAul i f fe , C . A . Inorg.
Chim. Acta 1979, 35, 265.
(40) Murray, S. G . ; Levason, W. ; Tuttlebee, H . E . Inorg. Chim. Acta 1981, 51, 185.
(41) Schenk, W . A . ; Frisch, J.; Durr, M . ; Burzlaff, N . ; Stalke, D . ; Fleischer, R.; Adam, W.;
Prechtl, F. ; Smerz, A . Inorg. Chem. 1997, 36, 2372.
(42) Tanase, T.; A i k o , T.; Yamamoto, Y . Chem. Commun. 1996, 2341.
(43) Geremia, S.; Mestroni, S.; Calligaris, M . ; Alessio, E . J. Chem. Soc. Dalton Trans.
1998, 2447.
(44) Lessing, S. F.; Lotz, S.; Roos, H . M . ; van Rooyen, P. H . J. Chem. Soc, Dalton Trans
1999, 1499.
(45) Carvalho, C. C ; Francisco, R. H . P.; Gambardella, M . T.; Sousa, G . F. ; Filgueiras, C.
A . L . Acta Cryst. 1996, C52, 1627.
(46) Filgueiras, C. A . L . ; Holland, P. R.; Johnson, B . F. G . ; Raithby, P. R. Acta Cryst.
1982,535, 2684.
77 References on page 75
Chapter 3
(47) Geremia, S.; Calligaris, M . ; Mestroni, S. Inorg. Chim. Acta 1999, 292, 144.
(48) Francisco, R. H . P.; Gambardella, M . T. P.; Rodrigues, A . M . D . D . ; de Souza, G . F.;
Filgueiras, C. A . L . Acta Cryst. 1995, C51, 604.
(49) Geary, W . J. Coord. Chern. Rev. 1971, 7, 81.
(50) Fogg, D . E . ; James, B . R. J. Organomet. Chern. 1993, 462, C21-C23, and references
therein.
(51) Mashima, K . ; Mikami , A . ; Nakamura, A . Chern. Lett. 1992, 1795.
(52) Otto, M . ; Parr, J.; Slawin, A . M . Z . Organometallics 1998,17, 4527.
(53) Dale, L . ; Tocher, J. H . ; Dyson, T. M . ; Edwards, D . I.; Tocher, D . A . Anti-Cancer
Drug Design 1992, 7, 3.
(54) Vashisht Gopal, Y . N . ; Jayaraju, D . ; Kondapi, A . K . Biochemistry 1999, 38, 4382.
ligands have been synthesized for the treatment of cancer, and one of these complexes,
[RuCl(r ] 6 -p-cymene)(N,Af ' -H 2 NCH 2 CH 2 NH 2 ) ] + , has shown anti-cancer activity against a
n
human ovarian cancer cell line (Section 4.7.2).
Previous work in this laboratory by Yapp et al. has suggested that trans-
RuCl 2 (disulfoxide) 2 complexes accumulate in cells and bind to D N A to a greater degree than 12,13
the cis isomers, while work by Cheu suggests that [RuCl(disulfoxide)(H 20)] 2(/^-Cl) 2
(disulfoxide = B E S E , B P S E , B B S E ) and [RuCl(BPSP)] 2 ( y u-Cl) 3 accumulate in cells, and bind
to D N A to a higher degree (-20 times more) than the mononuclear D M S O complexes and 14
-270 times more than the bis(disulfoxide) complexes. A l l the disulfoxide complexes tested
exhibited no significant toxicity toward Chinese hamster ovarian (CHO) cells. Two
79 References on page 96
Chapter 4
complexes synthesized in this thesis work, c z ' s - R u C l ^ D M S O ^ B E S E ) and [RuCl 2 (p-
cymene)] 2 (jU-BESE), were tested for anti-cancer activity using the M T T assay, and for
cytotoxicity using the C H O toxicity assay.
4.1.1 The MTT Assay
A need to determine the sensitivity of specific tumors and individualize therapy has
led to the development of a number of in vitro assays, and the M T T assay, which measures
mitochondrial dehydrogenase activity as a reflection of cell viability, shows considerable
promise in the screening and evaluation of potential new anti-cancer agents.1 5 Al ley et al.
have noted, in a feasibility study of the M T T assay, that "it appears suitable for initial-stage
16
in vitro drug screening". The assay is quick, taking 4-5 days, and involves addition of
M T T to tumor cells incubated with a test complex. The yellow tetrazolium form of M T T is
reduced, in active cells, by mitochondrial dehydrogenases to form purple formazan crystals
(Figure 4.1). A colourimetric determination is then able to quantify the percentage of viable
cells.
80 References on page 96
Chapter 4
(1) Tetrazolium (2) Formazan
Figure 4.1 The structure of (1) M T T [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (yellow) and (2) the formazan metabolite (purple).
4.1.2 The CHO Toxicity Assay
A cellular toxicity assay was used to test the viability of Chinese hamster ovarian
cells after incubation for 2 h with a test complex. The assay measures the colony forming
ability of the C H O cells (after 7 days) as a representation of cell viability and corresponding
complex toxicity.
4.2 Exper imental M e d i a and Solutions
M T T was purchased from Sigma. A l l media and solutions were purchased sterile, or
were sterilized through 0.2 urn filters (150 m L flask: 33 mm neck, Corning), unless
otherwise stated, and kept under sterile conditions before use. A l l bottles and pipette tips
were sterilized in an autoclave. Sterile experiments were performed in laminar flow
sterilization hoods, and equipment introduced into the hood was sprayed with 70 % ethanol.
81 References on page 96
Chapter 4
4.2.1 Media
For the M T T assay, Dulbecco's Modified Eagle's medium (1 L , Stem Cel l
Technologies) in l iquid form was supplemented with 10 % fetal bovine serum before use.
Hank's balanced salt solution (Stem Cel l Technologies) was used for washing the cells
before trypsinizing.
For the C H O toxicity assay, an a-modification of Eagle's minimum essential
medium powder (Gibco) was used in all incubation and C H O cell handling procedures. The
media were prepared by mixing M E M a-modification powder (1 L pkg), fetal bovine serum
10% (v/v, 100 mL), and 10,000 units penicillin/streptomycin antibiotic (Gibco) in 1 L of
deionized water. The solution was then stirred for 2 h at r.t., and split into 2 portions of
500 mL. One portion was buffered with 10 m M H E P E S , the p H adjusted to 7.3 with
4 M (aq.) N a O H , and filtered into a sterile glass bottle to prepare the a +/- medium. To the
other portion, N a H C 0 3 (1 g) was added, the p H adjusted to 7.3 with 4 M (aq.) N a O H , and
the a+/+ medium filtered.
A l l media were stored at 4 °C and warmed to 37 °C for use.
4.2.2 Phosphate Buffer Saline Solution (PBS)
The P B S was prepared by dissolving N a C l (4 g), KC1 (100 mg), N a 2 H P 0 4 (575 mg ),
and KH2PO4 (100 mg) in deionized water (500 mL). The solution was filtered, stored at
4 °C, and used at 37 °C, unless otherwise stated.
82 References on page 96
Chapter 4
4.2.3 Solutions of Ruthenium Complexes
For the M T T assay, the R u complex was dissolved in P B S (1-10 mL, 4 °C), and the
solution vortexed and left for 1 h before filtering through a 0.2 u,m needle filter (Nalgen).
The stock solution of the complex was then serially diluted with a+/+ medium in 6-well
plates (Falcon), according to prepared concentrations (Appendices A4.1 - A4.4), before
being added to the 96-well plate (Falcon).
For the C H O toxicity assay, the Ru complex was dissolved in P B S (10 mL, 4 °C) to
make a 2 m M stock solution. The solutions were vortexed and left for 1 h before filtering
through a 0.2 u,m needle filter and adding to the incubation flasks. Three concentrations
were chosen based on the amount of ruthenium complex available; 0.1, 0.5, and 1.1 m M
(Table 4.1, p.88).
4.2.4 Methylene Blue Solution
Methylene blue (200 mg) was dissolved in distilled water (100 mL) and the solution
was allowed to stand for 1 h prior to filtration. This solution was used for fixing and staining
colonies after incubation to assess colony forming ability.
4.3 M T T Assay Procedure
4.3.1 Cell Preparation
The cells used in the M T T assay experiments were obtained from a human mammary
cell line M D A - M B - 4 3 5 s . The cell concentrations were determined using a hemacytometer
and by diluting 50 U.L of cell suspension in 50 p L of trypan blue solution 0.4 % (Gibco) to
83 References on page 96
Chapter 4
stain dead cells. L ive cells were counted, the counts averaged and multiplied by the standard
experimental formula for a hemacytometer (the dilution factor and 104) to obtain the number
of cells/mL. The cells (1 x 105) were routinely maintained in T-75 flasks (Falcon) with
medium (~ 20 mL) at 37 °C in a NAPCO water-jacketed C 0 2 incubator (Precision Scientific)
under an atmosphere of 95 % air/5 % C 0 2 . The cells were trypsinized biweekly with 0.25 %
trypsin-EDTA (5 m L , Gibco) at 37 °C for 3 - 4 min (or until the cells were in suspension),
counted, and 1 x 105 were plated in a T-75 flask containing a+/+ medium (-20 mL). As a
backup, in the event of contamination, 1 x 104 cells were plated in a Tr25 flask (Falcon). To
obtain higher cell concentrations for experiments, 1 x 106 cells were plated in a T-75 flask
with a+/+ medium (50 mL) and grown for several doubling times, changing the medium
every few days.
4.3.2 MTT Cell Plating Procedu re and MTT Addition
The general procedure of the M T T assay is outlined in Figure 4.2. For each complex
tested, a 96-well plate was prepared by filling the six central wells of column C (control)
with 1 x 104 cells in 100 u L of medium (100 p L of cell medium were taken from a cell
suspension containing 1 x 105 cells/mL). This procedure was repeated for columns 1-8.
Medium (200 pL) was then added to column B to serve as a blank. The outside wells of the
plate were filled with sterile H 2 0 (200 pL) , and the plate was incubated for 24 h at 37 °C in a
95 % air/5 % C 0 2 incubator. After 24 h, the prepared stock concentration of Ru complex
(Section 4.2.3) was serially diluted with medium, according to a drug dilution chart with
concentrations chosen around the IC50 range of the complex (IC50 = concentration of drug at
which 50 % of the cells die). The complex was then added to the 6 wells containing cells,
84 References on page 96
Chapter 4
starting with the lowest concentration in column 8, and ending with the highest concentration
in column 1. 100 u L of medium were then added to column C and the plate was incubated
for 72 h.
After 69 h, the M T T (50 p,L of 2.5 mg/mL) was added to each experimental well in
the plate, which was incubated for a further 3 h. The wells were then aspirated to remove all
liquid, and D M S O (150 |xL) was added to each well to dissolve the formazan crystals. The
plates were then vortexed and the proportion of formazan was quantified by absorbance
readings at 570 nm using a Dynex Technologies spectrometer (96-well plate reader).
85 References on page 96
Chapter 4
II
B C 1 2 3 4 5 6 7 8 Incubate for 24 h
A d d Complex
96-Well Plate (10 x 15 cm)
IV
Incubate for 69 h
III
B C 1 2 3 4 5 6 7 8
Incubate for 3 h
A d d M T T
Figure 4.2 Design and Protocol of the M T T Assay.
I.
I I .
III. IV.
100 u.L of medium containing 1 x 10 4 cells was added to the shaded wells of the columns labeled C (control) and 1-8. Next, 200 p L of medium was added to column B (blank). After 24 h, a stock solution of complex, in PBS , was serially diluted with medium and 100 u L of the lowest concentration was added to each shaded well in column 8. This was continued from lowest to highest concentration for columns 7 through 1,respectively, then 100 p i of medium was added to the 6 shaded wells in column C. After 69 h, 50 p L of M T T (2.5 mg/mL) was added to each shaded well (B, C and 1-8). 3 h later, the plate was aspirated, 150 p L of D M S O was added, and the plate was read on a Dynex Technologies spectrometer (96-well plate reader) at 570 nm.
86 References on page 96
Chapter 4
4.4 C H O Toxici ty Assay Procedure
4.4.1 Cell Preparation
The cells used in all experiments were obtained from a Chinese hamster ovarian cell
line, chosen for its rapid growth and high plating efficiency. The cells (1 x 105) were
routinely maintained in T-25 flasks with oc+/+ medium (~ 5 m L ) at 37 °C in a
95 % air/5 % CO2 incubator. The cells were trypsinized three times a week with 0.05%
trypsin-EDTA (1 mL, Gibco) at 37°C for 3 - 4 min, counted using a hemacytometer, and
1 x 10 5 cells were plated in a T-25 flask. As a backup, in the event of contamination, 1 x 10 4
cells were plated in a T-25 flask. For higher cell concentrations, 1 x 10 6 cells were plated in
T-75 flasks with a+/+ medium (50 mL) and were grown for several doubling times with
medium replacement every 2 days.
4.4.2 Cell Incubation procedure
Prior to the day of the experiment, 1 x 10 6 cells were plated in each of 4 T-25 flasks
with a+/+ medium (5 mL). The cells were incubated for 13-15 h at 37 °C in an incubator
with 95 % air/5 % C 0 2 . After incubation, the medium was removed from the cells and
aliquots of a+/- medium and complex were added to the flasks according to the outline given
in Table 4.1.
The cells were then incubated with the complex for 2 h. After incubation, the
medium was decanted, the cells washed twice with PBS (2 mL) , and trypsinized with 0.05 %
trypsin-EDTA (1 mL) . A s soon as the cells were resuspended ( 3 - 4 min), a+i- medium
(9 mL) was added.
87 References on page 96
Chapter 4
Table 4.1 Aliquots of medium and Ru complex required for 0.1, 0.5, and 1.1 m M experimental concentrations.
Flask Number 1 (control) 2 3 4
Volume of a +/-medium added (mL)
10 9.5 7.5 4.5
Volume of 2 m M stock complex added (mL)
0 0.5 2.5 5.5
Concentration of complex (mM)
0 0.1 0.5 1.1
4.4.3 Cell Toxicity Assay
The toxicities of the complexes towards C H O cells under air were measured by
observing the colony-forming ability of cells. Samples (1 mL) were taken from the
incubation flasks (after incubation with the complex and resuspension of the cells, Section
4.4.2) and diluted immediately in fresh a+l- medium (9 mL, 4°C). This cell suspension was
then counted to determine the number of cells, and aliquots (10, 100, and 1000 pi) were
added to polypropylene tubes containing oc+/+ medium (5 mL) . This suspension was poured
into Petri dishes (Falcon) that were then incubated for 7 days to allow cell colonies to form.
After incubation, the oc+/+ medium was discarded, and the colonies stained with methylene
blue solution for ~ 9 min. The stain was then decanted and the dishes rinsed carefully with
cold water. The number of colonies per dish was counted and expressed as a plating
efficiency (PE) [PE = number of colonies counted/number of cells plated].
88 References on page 96
Chapter 4
4.5 M T T Assay Results
The M T T assay colourimetrically determines the number of cells that are
metabolically active after incubation with the test complex for 72 h. The growth inhibitory
effect of the added complex is expressed as a percentage of the control processed at the same
time [(OD of treated sample/OD of control) x 100]; the percentages were then graphed for
each concentration tested in order to create a dosage effect curve, and the curves were then
analyzed for the I C 5 0 . C / s - R u C l 2 ( D M S O ) 2 ( B E S E ) was found to have no toxicity toward
breast cancer cells at < 1.0 m M and an I C 2 0 > 3 m M (Figure 4.3). However, [RuCl 2 (p-
cymene)] 2( Ju-BESE) was found to have an I C 5 0 range of 0.345 - 0.360 m M (345 - 360 uM)
(Figure 4.4).
89 References on page 96
Chapter 4
120
5 60 -to > 50-O 40 -
30 •
20 •
10 -
0 J 1 1 1 . , 1 — r -
0.001 0.01 0.1 0.25 0.5 1 1.5
Concentration of RuCI2(DMSO)2(BESE) (mM)
(1)
5 5oJ
3 4 0 -
30 -
2 0 -
10 -
0 i 1 1 1 — r n 1 — r
0.1 0.5 1 1.51.752 25 3
Ctoncentration of Rua2(DMSO)2(BESE) (mM)
(2)
Figure 4.3 The graphs for two M T T assay trials. Graph (1) Shows the cell viability after treatment with c « - R u C l 2 ( D M S O ) 2 ( B E S E ) at drug concentrations from 0.001 to 1.5 m M . Graph (2) shows the same treatment but for concentrations from 0.1 to 3 m M . The I C 2 0 is > 3 m M .
90 References on page 96
Chapter 4
Figure 4.4 The top graph (trial 1) shows the cell viability after treatment with [RuCl 2 (p-cymene)] 2(p:-BESE) at drug concentrations from 0.0001 - 1.5 m M . The inset (trial 2) shows increased detail in the concentration range of the I C 5 0 from 0 .1 -1 m M . The I C 5 0 range is 345 - 360 u M .
91 References on page 96
Chapter 4
4.6 C H O Toxici ty Assay Results
The preliminary C H O toxicity results, expressed as a percentage of the control, are
shown in Figure 4.5 [Percent Viabili ty = (PE of the experimental concentration/PE of the
control) x 100]. The results show the percent viabilities of cells treated with cis-
R u C l 2 ( D M S O ) 2 ( B E S E ) were 73, 102, and 65 %, and for cells treated with RuC\2(p-
cymene)] 2( iu-BESE) the values were 76, 85, and 69 % at concentrations of 0.1, 0.5, and
1.1 m M , respectively. However, the actual P E values are low, ranging from 0.32 to 0.49 for
all treatments including the control (Figure 4.6); this suggests that some factor, other than the
presence of the complex, is diminishing cell viability. O f note, these data represent two
preliminary trials and further experiments are needed to determine definitively the
cytotoxicity of these complexes.
1 2 0
0 0 . 1 0 . 5 1.1
C o n c e n t r a t i o n o f C o m p l e x (m M )
Figure 4.5 Cellular toxicity results expressed as a percentage of the control for all concentrations tested. The data for d s - R u C l 2 ( D M S O ) 2 ( B E S E ) ( • ) and for RuCl 2 (p-cymene)] 2( /u-BESE) ( • ) are averages of two experimental conditions (10| iL and 100p:L).
92 References on page 96
Chapter 4
0.6
0 0.1 0.5 1 .1
C o n c e n t r a t i o n of C o m p l e x ( m M )
Figure 4.6 Cellular toxicity results expressed as P E for all concentrations tested. The data for c w - R u C l 2 ( D M S O ) 2 ( B E S E ) ( • ) and for RuCl 2(p-cymene)] 2( iu-BESE) ( • ) are averages of two experimental conditions ( lOuL and lOOuL).
4.7 Toxici ty and Anti-cancer Act iv i ty of Ruthenium Sulfoxide Complexes
4.7.1 Cis-RuCl2(DMSO )2(BESE)
The title complex at < 1.0 m M was found to have no toxicity toward breast cancer
17
cells, and an IC 2o > 3 m M (Figure 4.3). In comparison to cisplatin (IC50 = 10 p M ) , the
complex is not an effective anti-cancer agent against this breast cancer cell line. However,
the similarities in aqueous solution behaviour of this complex (Chapter 3, Section 3.3.1) with
that of c / s -RuCl 2 (DMSO )4 indicate the mixed sulfoxide complex may have anti-cancer
activity against other types of cancer and/or anti-metastatic activity. O f note, two complexes
made by the Khiar group, R,R- and S,S-trans-RuC\2(BMSE)2, were tested using the same
M T T assay procedure and cell line as reported in this thesis, and the IC50 ranges were 1.7-18
1.8 m M for both complexes.
93 References on page 96
Chapter 4
The preliminary C H O toxicity results suggest the title complex does not exhibit
significant toxicity at or < 1.1 m M . The results indicate percent viabilities for treated cells
are 73, 102, and 65 % at concentrations of 0.1, 0.5, and 1.1 m M , respectively. However, as
mentioned, the actual P E values are < 0.50 for all treatments including the control and
indicates a problem with the experimental design. These experiments involved trypsinizing
the cells biweekly and after incubation of the cells with R u complex, unlike the previously
13,14
reported toxicity procedures that used C H O cell cultures maintained in suspension.
Trypsin acts by breaking down the adherent cell membrane proteins which cause the cells to
stick to the flask wall. If the trypsin is left on the cells too long, or i f the cells have been
repeatedly trypsinized, the treatment wi l l affect the cell membrane properties and
consequently the cell viability. For further studies, it is recommended that cell cultures in
suspension be used.
4.7.2 [RuCl2(p-cymene)]2(/i-BESE)
The complex [RuCl20p-cymene)] 2(/i-BESE) was tested using the M T T assay and was
found to have an I C 5 0 range of 345 - 360 u M , showing effective anti-cancer activity when
17
compared with the corresponding IC50 of 10 p M found for cisplatin using this cell line.
The preliminary C H O toxicity results suggest that the title complex does not exhibit
significant toxicity at or < 1.1 m M with percent viability values of 76, 85, and 69 % at
concentrations of 0.1, 0.5, and 1.1 m M , respectively. As mentioned in Section 4.7.1 there
were problems with the experimental design, and further toxicity experiments should be
performed. Of note, the cells in the flask containing [RuClaGp-cymene^Ou-BESE) would not
responded to trypsin in the suggested 3 - 4 min incubation time and therefore a longer time
94 References on page 96
Chapter 4
and a higher dose of trypsin were needed to trypsinize the cells. The flask contents at 1.1
m M of complex would not respond to increased doses of trypsin even after 10 min so the
cells were removed from the bottom of the flask with a plastic scraper. It has been shown by
Geratz et al. that aromatic derivatives of diamidines can inhibit the activity of bovine
19
trypsin, and so it is possible that the aromatic-containing [RuCl2(p-cymene)] 2( Ju-BESE)
complex may also inhibit trypsin activity.
The in vitro activity of this complex is unknown, and the solution chemistry in a
biological environment is uncertain. It is suggested that [RuCl 20>cymene)] 2(,u-BESE) in
water gives [RuCl(/?-cymene)(BESE)]Cl (Chapter 3, Section 3.6.1), and this presumably
occurs in P B S ; however, at this stage it is unknown whether this charged species enters the
cell. Cummings et al. have shown that the similar cationic complex [RuCl(r| 6-/?-
cymene)(N, N ' - H 2 N C H 2 C H 2 N H 2 ) ] + , when reacted with D N A , forms a mono adduct with
n
guanine. This and related complexes exhibit a range of IC50 values from 6 - 200 u M for a
human ovarian cancer cell line compared with values of 0.8 u M for cisplatin and 6 p M for
carboplatin. 1 1 Therefore, the active species of the bridged [RuCl 2(p-cymene)] 2( iu-BESE)
complex may in fact be the [RuCl(p-cymene)(BESE)] + cation. Further research into the
activity of this cationic complex should be explored as the isolated species may have
increased activity at a lower dose than the parent compound.
95 References on page 96
Chapter 4
References
(1) Farrell, N . In Transition Metal Complexes as Drugs and Chemotherapeutic Agents
(eds. Ugo, R., James, B . R.); Kluwer Academic Publishers: Dordrecht, 1989; p 147.
(2) Alessio, E . ; Mestroni, G . ; Nardin, G . ; Attia, W . M . ; Calligaris, M . ; Sava, G . ; Zorzet,
S. Inorg. Chern. 1988, 27, 4099.
(3) Sava, G . ; Zorzet, S.; Giraldi , T.; Mestroni, G . ; Zassinovich, G . Eur. J. Cancer Clin.
Oncol. 1984, 20, 841.
(4) Sava, G . ; Pacor, S.; Zorzet, S.; Alessio, E . ; Mestroni, G . Pharm. Res. 1989, 21, 617.
(5) Alessio, E . ; Balducci, G . ; Lutman, A . ; Mestroni, G . ; Calligaris, M . ; Attia, W . M .
Inorg. Chim. Acta 1993, 203, 205.
(6) Clarke, M . J.; Zhu, F. ; Frasca, D . R. Chern. Rev. 1999, 99, 2511, and references
therein.
(7) Dale, L . ; Tocher, J. FL; Dyson, T. M . ; Edwards, D . I.; Tocher, D . A . Anti-Cancer
Drug Design 1992, 7, 3.
(8) Vashisht Gopal, Y . N . ; Jayaraju, D . ; Kondapi, A . K . Biochemistry 1999, 38, 4382.
(9) Allardyce, C . S.; Dyson, P. J.; El l is , D . J.; Heath, S. L . Chern. Commun. 2001, 1396.
(10) Morris, R. E . ; Sadler, P. J.; Chen, H . ; Jodrell, D . International Publication Number
W O 01/30790 A 1,2001.
(11) Cummings, J.; A i r d , R. E . ; Morris, R.; Chen, H . ; del Socorro Murdoch, P.; Sadler, P.
J.; Smyth, J. F . ; Jodrell, D . I. Clin. Cancer Res. 2000, 6, Supp. (S) Nov, abstract 142,
p 4494s.
(12) Yapp, D . T. T. Ph. D . Dissertation, University of British Columbia, Vancouver, 1993.
96 References on page 96
Chapter 4
(13) Yapp, D . T. T.; Rettig, S. J.; James, B . R.; Skov, K . A . Inorg. Chem. 1997, 36, 5635.
(14) Cheu, E . L . S. Ph. D . Dissertation, University of British Columbia, Vancouver, 2000.
(15) Bellamy, W . T. Drugs 1992, 44, 690.
(16) Alley, M . C ; Scudiero, D . A . ; Monks, A . ; Hursey, M . L . ; Czerwinski, M . J.; Fine, D .
L . ; Abbott, B . J. ; Mayo, J. G . ; Shoemaker, R. H . ; Boyd, M . R. Cancer Res. 1988, 48,
589.
(17) Sartor, J. ; Mayer, L . Unpublished data; through collaboration with the BC Cancer
Research Centre, 2001.
(18) Araujo, C . S.; Khiar, N . ; Huxham, L . ; James, B . R. Unpublished data, on-going
collaboration. 2001.
(19) Geratz, J. D . ; Cheng, M . C.-F. ; Tidwell , R. R. J. Med. Chem. 1976,19, 634.
97 References on page 96
Appendix 1
Appendix 1
Crystal Structure Data
Al. 1 Crystal Structure Data for RuCl2(DMSO)2(BESE)
Figure A l . l Stereoview of R u C l 2 ( D M S O ) 2 ( B E S E ) .
98
66
T 01 s O O I ||
a § c o d
iii G s a .2
jj N c. i3 & c o C
H D •5 < 3
W
_ « to S i 5 £ cj -a
O > j ! 6 d ? i: ir. oi
a:
to Cl
§
5 a. 3
o
p d K o
c5
c E
E £
<2 n 2 g " «? • O O N H A Ol
II II II II -•0 U ^
E
xipnaddy
'3. £
6
E
fe
001
1/3 1-H
•— oo
- - ^ O ! . - ^ „
C 2. w 2. CN co >—<
M IM CS i-i i— o —* n
CM s CO CM n
00 57 o o O o a U O u O
xipnaddy
xipnaddy
Appendix 2
Crystal Structure Data
A2.1 Crystal Structure Data for [RuChtp-cymene)] 2(p.-BESE)
Figure A2.1 Stereoview of [RuCl 2Op-cymene)] 2(/i-BESE).
103
SOI
M i-t
o <—
n r-
E o
< •
10 o OO Ci o CM PI Tf m o co CJ < 0" < a m o —< CM CM CM CM CM CM" to r— 00* cn
o u CJ CJ o cj CJ CJ o CJ O CJ X X X X X X X X X X X X
o — — i —
10 O I o» oo
T in >—'
-H t-( io
o o oo .-. to -4
l-H O
E o
< — = CM
H « Di oi
2- fr oo o 5 O D 0 5 •7 o O o u O u o O O o o O O
xipuaddy
901
— — <M (M CN +
+
« «-H in oo I C S O I-- ^ r- e-o r> « r- 10 oo , •W - V CO TJ- +
s u
' i o
en CQ < < ca
T m CO to CM CN fN a X K
CN ~
o o
< o 2 < <
CN m CM
CQ rt
u «! t o "
H(2
0A
)
a a SS a a a a a a a a H(2
0A
)
m y CQ < <: a CJ < o o CN CN n CO •a*
CN CN CN Cl CN CN CN
X a 3 a a a a a a a
xipnaddy
LOl
°°. ~ x6 t~ o o> o o CO 30 O i— —<
t-1 i j .
-3* i_i
CM CN CM
3 3
ce" 3
. « Ru(
3
cc CM CM m ao
CM "S 00 . CM to CM
CO to o o u L> o o u o o o
C CM 3 £»
Q ^7 CM Tf I O C S — ' C l d O C l M 0 4 0 0 O t— G" OD
u o o
CM" CM* C*4 CM
"a" c§
3
CC "a-
CC CO
u u " o o U
xipnaddy
801
CN — ' C N
CM r̂" CN —
CM —• -— CO C l 0 4 « ri
0? U U
O .— w
-a1 o
o o u r- 00 oo
C4 to" CM
D O O c o C C O O O
® "H" 2 S a cc CJ CJ
^ CM CM
CJ t/) CS CC
CM* ^f" CN CM?
at rr CN*
CN
cj cj o
CM '
o u cj" o cj CN —I
u cj
00 *-i —
o u u ' u
I i £ S « cc; ct o
OO U3 00 Cl 1- c> 00 00 CM t
3 CN CM o i CD o CO CN O CJ u CJ u u CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ o
p CM CM CN CN CM CM CN CN
p 3 3 3 3 « CC o i CC CC CC CS , a;
£ * err CN" ?? U O u CJ CJ ' CJ
j xipnaddy
3* is
c o u o o U
•- ' . — . CN
"i5 C ^ . . . . . . ^ - . . . . . H . « O CJ
601 q — to 00 -H m m IO (O to lO m i.O ,-. r r OO 00 U3 LO iO
x o ' q o o o o o o o o o 0 0 0 0 0 0 0 0 0 0 0 o o
3 ^> s — S" O
oo" DO O 5* O?
(aoi: - S ^ n s- eg" 13
B)
CJ a: o C o o Sf sf o O o u O o X in O O O 3=
xipuaddy
Appendix 3
Appendix 3
Crys ta l Structure Data
A3.1 Crystal Structure Data for [RuCl(p-cymene)(BESE)]PF6
Figure A3.1 Stereoview of [RuCl(p-cymene)(BESE)]PF 6 .
I l l
zu
* '3
_ § S
fa. "I g =
a!
-a
S S
£ 5
E
2
s 1 I 5
a •a
o
CL
o
u
- E ~ t o
& «
in II II II
a o
. u o a
S P
o 2 SC a O d
s &
xipaaddy
E I
•a a
3 5
£11
xipnaddy
r-< r - CM
CM . - .
t~- 1— T-1
<
§ f-T oo" cT
CO c-^ GO
CM r-H
— — J—
S CM cn CM i -
£ CJ> 0 —
"S o o u u u o o CM CQ CQ CQ CO CM CO
u.
xipuaddy
911
_̂ co o CO T OO CN CO m OO OO CM CM CM CM CM ro
Cu CJ O CJ CJ cj CJ CJ O u O O O CJ
o co co i - cn CM CO r - h- Ch —' CM tM CM CM CM CM
CU u O O a CJ CJ o CJ o CJ cj
CM
t i c
JS
g CM CM- o* T? Ch CO CM 5" o CM (O CM CM CM CM CO CO « u. CJ o CJ CJ CJ CJ U o a O CJ CJ CJ
c o co OJ CO CO »o Os 5 CM r- 00 i— CM CM CM CM CM a a. o CJ CJ CJ U O u CJ CJ a U CJ o
e p 3 « 3
M cc cc K cc C/] Cu
& E ^ ^ ^ CM" ^ co us r - T ^
3 ^ c j w u c j o 5 ? c j c j u o u c j o
E c ^ a .— CM
H * t f c d c e c s e £ c c ' c d e c - c d : ^
xipnaddy
LU
CO in 00 CO 00 OO 00 00 o O —i CN CN CM CN CN CN CN CN CN CN CN — — rs CN CN CN O u cj CJ cj CJ CJ CJ O CJ o CJ CJ U CJ CJ CJ o U CJ CJ CJ cj
oo -rr CN CM
O CJ
66
.4(2
!
36
.5(2
]
77
.2(2
]
36
.0(2
]
77
.5(2
]
65
.7(2
]
11
5.3
(!
i05
.i(;
108.2
(:
ii8
.i(:
114
.7(:
o t~ o 1
16
.3C
r~ CM
C(2
5) t~
CM
O
to CM
C C(2
8)
oo CM
y O o 0(2
)
C(5
)
C(5
)
0(3
)
f*< CN >—I
o o
t-i CN
lO o CN CN CN CN CN CN CN CN CN CO
CJ CJ CJ CJ c£ o CC o cc O cC CC o
s 3 £ H 3
re o u 0 u FT
u O y y
3 cn O U 0O
o CM" H 2 5' CM
y O y y O y y y y y y CM CM • CM
y y y
E ~ c r ~ ~ _ _ _ _ _ ^ ~ — — ~ - -? ^ sr ff ^ « C J C J C J C J c/i cn - cn cn c"n ./T L O CJ O CJ CJ CJ CJ CJ O O O CJ cTf
xipnaddy
•811
a CO
ST CM
tu
B CO
b.
s ca a co
5T u. 5T a ST
ca ST
OO « ST £T &.
O S~ ffl Cu ST b.
o ST
•o o c o ti.
CJ m CJ b,
57 ST
. — ' co c^-" ao m CD OO .-I
CJ cs ET
S -
m C J
CJ CJ ca ca o C J CJ CO
sr u . ti. a co
2- S. ST ST cj
ST CO C O :4
C) a
C J 4B)
ST ti. ti. b.
— .-. ST ST ST K ST
CJ CJ
o CJ
6" C O ;3
C) o
C O
fc L i . b. ti. tu
m C J b.
ffi CO
ST
ti. CQ
ST
C71 r~ EV> ST
s < CJ CJ o CQ < CJ CJ CQ c a < CJ CJ ca ca o U a a CJ C O •ft C O >— C O CO c o co CJ CJ C N C J u . b . b . b . b . ti- ti. b , b . b . b . b . b . fcu ti. ti. b . ti. ti. b , b . b . b . b .
o
E
0 . 0. a, ti. c u ti. a. a. Cu CU ti. cu cu CU ft- a, CU cu Cu CU Cu Cu
< < •< < < < < < < < < < < < < < < < < < < < CJ C J CJ C M CJ C N co C O C O C O C O CO TP TT
b , ti. b . ti. ti. ti. b , ti. ti. ti. b . ti. ti. ti. b . ti. u . U . ti. b . b , ti. b . ti.
eo — - — - ,—, ao
5 § i CO Ch
CC r-. CO
< < U CJ m a < CJ O a a CJ CJ a a CJ m a C N C J C N *c CO C J TT CN r-l C O C O CO C O CO
b. b. b. ti. b. ti. b. b. [ L , ti- b. In b. b. ti. tu fcu ti. Su ti. b. ti. fcu
^ B < ' < < < < < < < < < < < : < < < < < < < < < < W ° C l w < J ^ " « C M C M C M C 4 C > l C N c O c O C O e O C O T l « ' T T r T l >
xipaaddy
6 CM
OS CJ
CM — •—• CM "—•
u t> u o
xipuaddy
OZl ^ C S P - i O T P O D a q T P O > t O O r ~ . O a q
g o o o o o o o o o o o o o o o o o o o o o o o o
CO to CO ao Cft CS CS CO LO to to p- cn Oi 0 CS CN CN cN CN CN CN CN CS 50 CO CO CO CO , CO CO co CO CO CO CO TP TP TP X EE X s* X X CC X X X X X ic X X X 3 3 ' X X X x X X X
TP TP tf} UO L.O CO CO CO P- P- r- 00 oo 00 0 . Cft 0 . 0 0 CS - CN CS CS CS
0 0 0 0 O O u 0 0 0 U O O O O 0 0 0 0 0 U 0 0
E 2 5 CJ o CJ
CN — K CJ CJ a en CJ
C S 5" 0 a K
o r -s s
I S. rt X s s
a
o CL-d CJ
CN w
a cj
0 O O O U U
O CO —
o" CS CS CS CS CO X X X X x" co ^2.
cTf O
0 es 0 CS CN CS CN
CS CS
CS CS
U O r j 0 O 0 0
(19)
TP CS CS (3
8)
CS 0 " TP
to O 0 X 0 X
t c s c s f N c o c o c o T p T f in a U O U O O O O Q U O U
CN CO
CJ 0 0 a
_ CS
CO CN CO
CJ a CO O in
CN CO c. CJ a a CJ a!
0 5 2 CO
O u CJ
2 2 s
§ £ S 2 S a CJ CJ CJ CJ
a a a
t o CO CO
0 u O
10 ID
CJ CJ
CM CO CO
CJ 0 CJ
C S «-f —v
—f p- I*. I-l H c f l e o O X O X f f i ' - c r t O w O X m r j U O f f i C S O y o s O O O O
xipnaddy
f t cs
m 00 Ch o O c C-l CS CS CS CS es cs cs CS es cs CO eO CO CO CO CO CO CO CO
CJ CJ o o o U O CJ CJ CJ CJ U U U U U
CS CS 00 CO CO OS •0 Oi o> CD lO CS CS CS CS CS CO CS TT CS iO CS »-o lO
{§ CJ O D O CJ CJ X U X X O X X
o to ao CO Tf CS oo c T P
g oi- CS O) oi CO CN oi r— o oi O c i o s s oi O s oi O oi
A4.1 M T T Drug Dilution Charts: First Trial with R u C l 2 ( D M S O ) 2 ( B E S E )
Table 1 Stock Solution Preparation
Compound R u C l 2 ( D M S O ) 2 ( B E S E ) Molecular Weight (g/mol) 510.19 Stock Used (g) 0.005 Diluent PBS Diluent volume (mL) 3 Initial working concentration 3.27E-03 Total working volume 3 Amount per well (pL) 100 Dilution Factor (200 uL total/100 uL drug vol.) 2
Table 2 Serial Dilution Data
Final cone. Volume of Working Volume of Diluent Volume remaining for (mM) Solution (mL) (medium, mL) Addit ion to M T T Plate (mL) 1.5 2.75 0.25 1.00 1 2.00 1.00 1.50 0.5 1.50 1.50 1.50 0.25 1.50 1.50 1.80 0.1 1.20 1.80 2.70 0.01 0.30 2.70 2.70 0.001 0.30 2.70 2.70 0.0001 0.30 2.70 3.00
122
Appendix 4
A4.2 M T T Drug Dilution Charts: Second Trial with R u C l 2 ( D M S O ) 2 ( B E S E )
Table 1 Stock Solution Preparation
Compound R u C l 2 ( D M S O ) 2 ( B E S E ) Molecular Weight (g/mol) 510.19 Stock Used (g) 0.03 Diluent P B S Diluent volume (mL) 6 Initial working concentration 9.80E-03 Total working volume 8 Amount per well (pL) 100 Dilution Factor (200 u L total/100 uL drug vol.) 2
Table 2 Serial Dilution Data
Final cone. Volume of Working Volume of Diluent Volume remaining for (mM) Solution (mL) (medium, mL) Addit ion to M T T Plate (mL) 3 4.90 3.10 1.33 2.5 6.67 1.33 1.60 2 6.40 1.60 1.00 1.75 7.00 1.00 1.14 1.5 6.86 1.14 2.67 1 5.33 2.67 4.00 0.5 4.00 4.00 6.40 0.1 1.60 6.40 8.00
123
Appendix 4
A4.3 M T T Drug Dilution Charts: First Trial with [RuCl 2(p-cyrnene)] 2(//-BESE)
Table 1 Stock Solution Preparation
Compound fRuCl 2 (p-cymene)l 2 (^-BESE) Molecular Weight (g/mol) 794.69 Stock Used (g) 0.0075 Diluent P B S Diluent volume (mL) 3 Initial working concentration 3.15E-03 Total working volume 3 Amount per well (pL) 100 Dilution Factor (200uL total/ lOOpX drug vol.) 2
Table 2 Serial Dilution Data
Final cone. Volume of Working Volume of Diluent Volume remaining for (mM) Solution (mL) (medium, mL) Addition to M T T Plate (mL) 1.5 2.86 0.14 1,00 1 2.00 1.00 1.50 0.5 1.50 1.50 1.50 0.25 1.50 1.50 1.80 0.1 1.20 1.80 2.70 0.01 0.30 2.70 2.70 0.001 0.30 2.70 2.70 0.0001 0.30 2.70 3.00
124
Appendix 4
A4.4 M T T Drug Dilution Charts: Second Trial with [RuCl 2 (p-cymene)] 2 (^-BESE)
Table 1 Stock Solution Preparation
Compound [RuCl 2(p-cymene)l 2(/^-BESE) Molecular Weight (g/mol) 794.69 Stock Used (g) 0.015 Diluent P B S Diluent volume (mL) 5 Initial working concentration 3.78E-03 Total working volume 4 Amount per well (pL) 100 Dilution Factor (200uL total/ lOOuL drug vol.) 2
Table 2 Serial Dilution Data
Final cone. Volume of Working Volume of Diluent Volume remaining for (mM) Solution (mL) (medium, mL) Addition to M T T Plate (mL) 1.5 3.17 0.83 1.33 1 2.67 1.33 1.00 0.75 3.00 1.00 1.33 0.5 2.67 1.33 1.20 0.35 2.80 1.20 1.14 0.25 2.86 1.14 2.40 0.1 1.60 2.40 3.60 0.01 0.40 3.60 4.00